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ABSTRACT 
 
Background: Obesity is associated with dyslipidemia, insulin resistance and glucose 
intolerance and together these components characterise the metabolic syndrome 
(Dandona et al. 2005). In the state of obesity, there are high levels of circulating free fatty 
acids and increased rates of fatty oxidation which inhibit glucose oxidation. This: (i) 
reduce the heart‘s contractile ability, (ii) exacerbates ischemic/reperfusion injury and (iii) 
decreases cardiac mechanical function during reperfusion (Kantor et al. 2000; Liu et al. 
2002; Taegtmeyer, 2000). 
 
Aim: The aim of our study was to investigate the effect of inhibiting fatty acid oxidation, 
with oxfenicine (4-Hydroxy-L-phenylglycine), on (i) cardiac mechanical function, (ii) 
mitochondrial respiration, (iii) myocardial tolerance to ischemia/reperfusion injury, (iv) 
CPT-I expression, MCAD expression, IRS-1 activation, total GLUT- 4 expression and 
(v) the RISK pathway (ERK42/44 and PKB/Akt). 
 
Methods: Male Wistar rats were fed a control rat chow diet or a high calorie diet (HCD) 
for 16 weeks. The HCD caused diet induced obesity (DIO). The animals were randomly 
divided into 4 groups [Control, DIO, Control + oxfen and DIO + oxfen]. The drug was 
administered for the last 8 weeks of feeding (200mg/kg/day). Animals were sacrificed 
and the hearts were perfused on the Langendorff perfusion system. After being subjected 
to regional ischemia and two hours of reperfusion, infarct size was determined. A 
separate series of animals were fed and/or treated and hearts were collected after 25 
minutes global ischemia followed by 30 min reperfusion for determination of GLUT- 4, 
CPT-1, IRS -1, MCAD, ERK (42/44) and PKB/Akt expression/phosphorylation using 
Western blot analysis. A third series of hearts were excised and used for the isolation of 
mitochondria. 
 
Results: In the DIO rats, chronic oxfenicine treatment improved cardiac mechanical 
function by improving mitochondrial respiration. Oxfenicine inhibited CPT-1 expression 
but had no effect on MCAD or GLUT- 4 expression. Oxfenicine decreased IRS-1 
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expression, but not IRS-1 activation. Oxfenicine also improved myocardial tolerance to 
ischemia/reperfusion without activation of the RISK pathway (ERK & PKB). In the 
control rats, chronic oxfenicine treatment worsened cardiac mechanical function by 
adversely affecting mitochondrial respiration. Oxfenicine also worsened myocardial 
tolerance to ischemia/reperfusion in the control rats without changes in the RISK 
pathway (ERK & PKB). Oxfenicine had no effect on CPT-1, MCAD or GLUT- 4 
expression.  Oxfenicine increased IRS-1 expression, but not IRS-1 activity.  
 
Conclusion: Chronic oxfenicine treatment improved cardiac mechanical function and 
myocardial resistance to ischemia/reperfusion injury in obese animals, but worsened it in 
control animals. The improved cardiac mechanical function and tolerance to 
ischemia/reperfusion injury may be due to improvement in mitochondrial respiration. 
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UITTREKSEL 
 
Agtergrond: Vetsug word geassosieer met dislipidemie, insulien weerstandigheid en 
glukose intoleransie, wat saam die metaboliese sindroom karakteriseer (Dandona et al. 
2005). Met vetsug is daar ‗n hoë sirkulasie van vetsure, sowel as verhoogde vertsuur 
oksidasie wat gevolglik glukose oksidasie onderdruk. Dit: (i) verlaag die hart se vermoë 
om saam te trek, (ii) vererger isgemiese/herperfusie skade en (iv) verlaag kardiale 
effektiwiteit gedurende herperfusie (Kantor et al. 2000; Liu et al. 2002; Taegtmeyer, 
2000). 
 
Doel: Die doel van die studie was om die effekte van vetsuur onderdrukking m.b.v. 
oksfenisien (4-Hidroksie-L-fenielglisien) op (i) meganiese hart funksie, (ii) mitokondriale 
respirasie, (iii) miokardiale toleransie teen isgemiese/herperfusie skade, (iv) CPT-I 
uitdrukking, MCAD uitdrukking, IRS-1 aktiwiteit, totale GLUT-4 uitdrukking en  (v) die 
RISK pad (ERK42/44 en PKB/Akt) te ondersoek.  
 
Metodes: Manlike Wistar rotte was gevoer met ‗n kontrole rot dieet of ‗n hoë kalorie 
dieet (HKD) vir 16 weke. Die HKD lei tot dieet-geïnduseerde vetsug (DGV). Die diere 
was lukraak verdeel in 4 groepe [kontrole, DGV, kontrole + oksfen en DGV + oksfen]. 
Die behandeling met die middel was toegedien vir die laaste 8 weke van die voeding 
protokol (200mg/kg/dag). Die diere was geslag en die harte was geperfuseer op die 
Langendorff perfusie sisteem. Na blootstelling aan streeks- of globale isgemie en 2 ure 
herperfusie was infark groottes bepaal. ‗n Aparte reeks diere was gevoer en/of behandel 
en die harte was versamel na 25 minute globale isgemie gevolg deur 30 minute 
herperfusie vir die bepaling van GLUT-4, CPT 1, IRS -1, MCAD, ERK (42/44) en 
PKB/Akt uitdrukking/aktivering d.m.v. Western blot analise. ‗n Derde reeks diere was 
gebruik vir die isolasie van mitokondria. 
 
Resultate: In die DGV diere, het kroniese oksfenisien behandeling meganiese hart 
funksie verbeter d.m.v. die verbetering van mitokondriale respirasie. Oksfenisien het 
CPT-1 uitdrukking verlaag terwyl GLUT- 4 en MCAD uitdrukking nie geaffekteer was 
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nie. Oksfenisien het IRS-1 uitdrukking verlaag, maar nie IRS-1 aktiwiteit nie. 
Oksfenisien het ook miokardiale weerstand teen isgemiese/herperfusie verbeter met 
sonder aktivering van die RISK pad (ERK & PKB). In die kontrole diere, het kroniese 
oksfenisien behandeling die meganiese hart funksie versleg d.m.v. negatiewe effekte op 
mitokondriale respirasie. Oksfenisien het die miokardiale weerstand teen 
isgemiese/herperfusie van die kontrole rotte versleg sonder veranderinge in die RISK pad 
(ERK & PKB). Oksfenisien het geen effek gehad op CPT-1, MCAD en GLUT-4 
uitdrukking nie. Oksfenisien het IRS-1 uitdrukking verhoog, maar nie IRS-1 aktiwiteit 
nie. 
 
Samevatting: Kroniese oksfenisien behandeling het die meganiese hart funksie en 
miokardiale weerstand teen isgemiese/herperfusie skade in die vet diere verbeter, maar 
versleg in die kontrole diere. Hierdie verbetering van meganiese hart funksie en 
weerstand teen isgemiese/herperfusie skade kon dalk wees a.g.v. ‗n verbetering in 
mitokondriale respirasie. 
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INTRODUCTION 
 
Over the past couple of decades obesity has increased at an alarming rate and given rise 
to the observation that it is currently exceeding the boundaries of diseases that threatens 
human life (Mathieu et al. 2008). Since the surpassing of the Palaeolithic era and the 
progression into the era of western lifestyle-popularity, humans gradually diverted from 
the diet of the pre-agricultural Hunter-gatherers, to the much indulged western diet of 
today. A variety of factors that include poor dietary composition (high-trans fatty acids, 
high saturated fatty acids and high refined sugar content), socio-economic changes, 
agricultural developments and technological advances appears to be the leading cause of 
the increased incidence of obesity globally (Hammer et al. 2008; Opie, 2009; Poirier et 
al. 2006). 
 
In the United States of America alone, 65% of adults over 20yrs of age are either 
overweight or obese and deaths ascribable to obesity are 280184/year. South Africa now 
also has an obesity record, mimicking that of the USA, with approximately 50% of the 
adult female population ≥ 30yrs classified as obese (Cordain et al. 2005). Obesity within 
the South African context appears to be a complicated matter. In 2001 a census was done 
and 44.8 million people were counted. The culturally diverse South African population 
consisted of 76 percent blacks, 13 percent whites, 9 percent of mixed ancestry 
(coloureds) and 2.5% Indians (Puoane et al. 2005). The census also revealed that people 
continuously migrates from rural to urban areas. A recent study concludes that the 
percentage of the population in urban areas to more than 60 percent. The largest 
migrating group are black people from the rural areas (Puoane et al. 2005). 
 
The emergence of diseases in the previously disadvantaged groups in South Africa 
initially occurred in the coloured population, which was the first to experience 
urbanization, industrialization, upward mobility and adoption of the typical western 
lifestyle (See review by Puoane et al. 2005). The black groups are currently in transition 
of this process and therefore there is now a clear link between urbanization and 
emergence of diseases in these groups. In the black group the degree of urbanization is 
 xxv 
directly linked to the increasing consumption of the typical western diet, smoking 
cigarettes at an early age in black women, and the development of diabetes and 
hypertension (Bourne, 1994; Steyn et al. 1994; Steyn et al. 1996). Other factors 
contributing to the development of obesity in transitional countries include 
environmental, socio-economic, behavioural and cultural factors (WHO, 2000). Both 
research and case studies indicate that environmental and socioeconomic factors 
contribute to the emergence of obesity in urban black African women (Puoane et al. 
2005). 
 
These statistics give both researchers and the public a glimpse into the magnitude of the 
global obesity pandemic. Many continents, including Africa, have adopted a sedentary 
lifestyle (lifestyle prone to inactivity), which in addition to the above mentioned factors, 
exacerbates already worrying statistics. This brings health experts and scientists to the 
conclusion that obesity is single handedly threatening human health and also explains 
why obesity has received much attention over the past few years (Reaven, 2005; 
Lopaschuk, Folmes & Stanley, 2007; Lopaschuk et al. 2010; Franssen et al. 2008). 
 
Obesity is one of a cluster of physical- and metabolic abnormalities that together 
characterise the metabolic syndrome. Obesity, and particularly visceral/central obesity, is 
associated with certain metabolic abnormalities/cardiovascular risk factors that include 
dyslipidemia, hypertension, glucose intolerance, systemic inflammation, obstructive sleep 
apnoea/hypoventilation and a pro-thrombotic state (Poirier et al. 2006). The importance 
of body fat distribution on the severity of obesity related diseases has only in recent years 
become better understood. Consensus is that metabolic perturbations, associated with the 
metabolic syndrome, is worsened by an increased amount of visceral fat which is 
commonly known as central obesity (Mathieu et al. 2008).  
 
There is increasing evidence implicating increased systemic oxidative stress (an 
imbalance between oxidants & antioxidant systems in the favour of oxidants) in the state 
of obesity (Diniz et al. 2008). Additionally, the accumulation of adipose tissue leads to (i) 
an altered inflammatory state with lowered adiponectin levels, increased pro-
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inflammatory cytokine levels (interleukin-6, C-reactive protein and TNF-α-levels), (ii) 
altered lipid profiles i.e. dyslipidemia (low High Density Lipoproteins & High Low 
Density Lipoproteins), (iii) a variety of adaptations/alterations in cardiac structure and 
function .i.e. cells secreting various locally acting molecules, cell dysfunction/death, 
lipotoxicity, left ventricular diastolic dysfunction and left ventricular hypertrophy as well 
as (iv) insulin resistance (Poirier et al. 2006; Taegtmeyer, 2000).  
 
Recent work has shown that, hearts form obese rats fed an experimental high 
carbohydrate and -fat diet, were hypertrophied. This was illustrated by the increase in 
ventricular weight, ventricular weight-to-tibia length, left ventricular posterior wall 
thickness and an increase in cardiomyocyte size (Du Toit et al. 2008). With obesity, 
ectopic lipid accumulation in the myocardium (as a result of the elevated circulation of 
free fatty acids and triglycerides) impairs cardiac systolic and diastolic function (Rasouli 
et al. 2007). However, it is almost impossible to adequately discuss the effects of obesity, 
without touching on the metabolic syndrome.  
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CHAPTER 1 
LITERATURE REVIEW 
 
A marked increase in the number of metabolic syndrome cases has occurred worldwide 
(Eckel, Grundy & Zimmet, 2005; Miranda et al. 2005; Nguyen et al. 2008; Lin & Sun). 
This increase is due to increases in the incidence of obesity and diabetes. There is thus an 
urgent need for effective therapeutic strategies. 
 
 
Metabolic syndrome (MS) & Cardiovascular disease 
1.1 Metabolic Syndrome 
1.1.1 Definition of the Metabolic Syndrome 
 
This syndrome was originally defined as a condition consisting of several classical 
cardiovascular risk factors that include insulin resistance, hypertension, 
hyperinsulinemia, dyslipidemia, type II diabetes (T2DM) and glucose intolerance. MS is 
the consequence of an excessive caloric intake and a sedentary lifestyle (Eckel, Grundy & 
Zimmet, 2005). An individual is diagnosed with the MS if they present with two or more 
of these abnormalities. The prevalence of MS increases with age as illustrated by data 
gathered in the USA: One in three adults between the age 50 and 59 have MS when 
compared with younger adults (Caglayan et al. 2005). 
 
Patients with MS are four times more likely to develop cardiovascular pathologies in 
comparison with patients without this condition (Bugger & Abel, 2008; Caglayan et al. 
2005; Klein et al. 2002). 
 
Pathologies associated with MS include: coronary artery disease, heart failure and 
ischemic intolerance. The metabolic syndrome is also associated with renal dysfunction 
and aorta wall stiffness (Caglayan et al. 2005; Klein et al. 2002). 
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1.1.2 The Development of the MS 
 
The general rationale is that certain factors, including a sedentary lifestyle, excessive 
food intake and genetic predisposition, lead to either visceral- or general obesity. Thus 
the point of origin of MS is considered to be obesity. This increase in body fat causes 
dyslipidemia which in turn leads to insulin resistance and ultimately MS (Reaven, 2005). 
See figure 1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A graphical representation of how MS develops over time (Adapted from 
Reaven, 2005; Smith 2006) 
Sedentary 
lifestyle 
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Type 2 diabetes mellitus (T2DM) is a known consequence of MS (Eckel, Grundy & 
Zimmet, 2005; Miranda et al. 2005; Nguyen et al. 2008; Lin & Sun, 2010). Together with 
obesity, the incidence of T2DM is increasing rapidly and many researchers devote their 
scientific efforts towards developing treatments to combat T2DM. This condition 
however remains a major concern. 
 
 
1.1.3 MS and Type II Diabetes Mellitus (T2DM)  
 
T2DM is the more prevalent form (90%) of diabetes, with a polygenic background, 
which is acted on by environmental factors in order to enable its distinctive clinical 
presentation (Thim et al. 2006). It is described as a chronic metabolic disorder and a non-
insulin-dependent type of diabetes that is the result of obesity, insulin resistance as well 
as a β-cell secretory defect and can go undiagnosed for many years (Carley & Severson, 
2008; Scheuermann-Freestone et al. 2003). The same factors that lead to MS is the cause 
of T2DM. Therefore T2DM is usually associated with the metabolic syndrome (Thim et 
al. 2006). Patients with this form of diabetes have: (i) concomitant hypertension or 
cardiovascular disease and (ii) limited exercise tolerance, which have been associated 
with decreased glycemic control and microvascular disease (Scheuermann-Freestone et 
al. 2003).  
 
The pathogenesis of T2DM is described as multifactorial with both genetic and 
environmental contributions such as diet and physical activity. There is now substantiated 
scientific evidence suggesting that T2DM is strongly associated with visceral fat 
accumulation. Furthermore many patients with T2DM have either normal or elevated 
LDL-cholesterol levels or decreased HDL-cholesterol levels (Scheuermann-Freestone et 
al. 2003). 
 
Statistics show that approximately 15% of all deaths in American patients with T2DM 
are ascribed to cardiac disease without notable symptoms of coronary artery disease 
(Christoffersen et al. 2007). T2DM affects about 250 million people worldwide and it is 
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estimated that by the year 2025, the prevalence of this disease will reach 380 million 
people (Hegarty et al. 2009). Epidemiological studies have shown that in diabetic 
populations, the incidence of myocardial infarction increases with subsequent heart 
failure. It is reported that diabetes presents as a coexisting condition in 20-35% of heart 
failure patients (Chandler et al. 2007). Furthermore, this heterogeneous disorder accounts 
for 90-95% of all diabetes cases (Scheuermann-Freestone et al. 2003). It has been shown 
that, T2DM patients with normal cardiac morphology and function, displayed impaired 
metabolism of high-energy phosphates, in both cardiac- and skeletal muscle 
(Scheuermann-Freestone et al. 2003). 
 
The metabolic syndrome comprises of different components which include obesity, 
insulin resistance, glucose intolerance, dyslipidemia/hypercholesterolemia and 
hypertension (Caglayan et al. 2005). However, only the components relevant to this 
thesis will be discussed. The MS has a profound deleterious impact on the incidence and 
development of cardiovascular disease, through these above mentioned components. 
 
 
1.2 Components of MS and its Impact on Cardiovascular Disease 
 
1.2.1 Obesity 
 
A person is traditionally classified as obese based on their body mass index (BMI) 
measurement, as set out by the world health organisation (WHO) standards/guidelines. A 
person with a BMI measurement ≥ 30-40kg/ m2 (Class I-III) is classified as obese (See 
review by Rasouli & Kern, 2008). Obesity is a storage disorder, which occurs when there 
is an imbalance between calorie intake and -utilization over a period of time (Mathieu et 
al. 2008; Poirier et al. 2006). The ability of obesity to cause damage to the myocardium 
could be related to the selected metabolic pathway and fuel utilization, whether fatty acid 
oxidation or glucose oxidation (Diniz et al. 2006). Obesity is a heterogeneous condition 
with a complex etiology which is implicated to decrease life expectancy and is associated 
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with numerous medical complications such as cardiovascular disease (Mathieu et al. 
2008; Lima-Leopoldo et al. 2008). 
 
Obesity is associated with systemic inflammation during which adipocytes secrete 
numerous factors known as adipokines. This ultimately led to the classification of the 
adipose tissue as an endocrine organ and part of the innate immune system. Adipokines 
include: leptin, tumor necrosis alpha (TNF-α), adiponectin, resistin and visfatin. TNF-α is 
an adipokine that has been indicated as a possible mediator of insulin resistance with 
controversial effects on the heart (Xu et al. 2002, Torre-Amione et al. 1996; Jobe et al. 
2009). The administration of TNF-α to rats causes insulin resistance and the 
neutralization of TNF-α in vivo reverses both hepatic and skeletal muscle insulin 
resistance (Lang et al. 1992; Borst et al. 2004; Borst & Conover, 2005). The above 
mentioned adipokines are considered important determinants of insulin resistance, via 
circulating hormonal effects or – local adipocytic effects and contributes to the regulation 
of cardiac metabolism and inflammatory responses (See review by Rasouli & Kern, 
2008). 
 
The adipose tissue derived macrophages also play an important role in obesity mediated 
systemic inflammation, by secreting cytokines such as IL-6 (Dandona et al. 2005). 
Obesity: (i) affects the cardiovascular system through its influence on certain risk factors 
(dyslipidemia, hypertension, and glucose intolerance) and (ii) is considered to be an 
independent risk factor for the development of cardiovascular disease (Poirier et al. 
2006). Obesity is not just an independent risk factor for cardiovascular disease but is 
mostly associated with cardiovascular disease and even believed to cause cardiovascular 
disease (Poirier et al. 2006). 
 
The incidence and development of cardiovascular disease (CVD) have been shown to be 
the result of elevated plasma LDL-cholesterol levels or decreased HDL-cholesterol 
levels. Under normal conditions the lipid balance is: high HDL and low LDL levels. 
However, this disturbance in the LDL: HDL ratio is caused by visceral obesity 
(Scheuermann-Freestone et al. 2003). Therefore visceral obesity is of great significance 
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in the development of cardiovascular disease (CVD). Other possible causes of CVD are 
(i) consumption of foods which are high in trans-fatty acids and saturated fatty acids as 
well as (ii) genetic predisposition (Guttmacher & Collins, 2003; Guize et al. 2008) 
 
 
1.2.1.1 Importance of visceral obesity in cardiovascular disease 
 
It has been shown that visceral obesity contributes to the development of coronary artery 
disease (Kobayashi et al. 2001). Visceral obesity is characterized by low high-density 
lipoprotein (HDL) cholesterol, high LDL cholesterol levels and low plasma adiponectin 
levels. In visceral adipose tissue there is a greater increase in the lipolytic response to 
noradrenalin (as indicated by the amount of FFA released) and this could be the reason 
for the resultant high LDL cholesterol and low HDL cholesterol levels. Furthermore it is 
believed that in the presence of visceral obesity adipocytes undergo certain changes 
which cause them to produce less adiponectin. Therefore reduced adiponectin levels are 
observed in visceral obesity (Kobayashi et al. 2001; Mathieu et al. 2008). In conclusion, 
visceral obesity contributes to the development of cardiovascular disease (CVD) by 
means of high plasma LDL cholesterol, low HDL cholesterol levels and low adiponectin 
levels. All of these factors promote the progression of arterial plaques, artherosclerosis 
and thus CVD (Mathieu et al. 2008; Cefalu, 2008; Vague, 1956). 
 
 
1.2.1.2 Obesity and cardiac remodeling 
 
Obesity leads not only to increased adipose tissue depots but also to significant lipid 
accumulation in the heart. Thus with the occurrence of obesity, there are adaptations or 
alterations in the cardiac structure that include: (i) ventricular chamber dilation caused by 
an obesity induced shift in the Frank-Startling curve and a consequential increase in left 
ventricular filling pressure and -volume, (ii) left atrial enlargement, (iii) adipositas cordis 
or gradual fat accumulation within in heart muscle fibres, which cause myocyte 
degeneration and cardiac conduction defects and lastly (iv) left ventricular hypertrophy, 
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due to an increased demand on the heart to pump blood to systemic circulation because 
blood dependent tissue (adipose tissue) has increased (Poirier et al. 2006; Opie et al. 
2006). 
 
 
1.2.1.3 Obesity and cardiac function 
 
With obesity, the deposition of fat can impair cardiac function in two ways: (i) by 
physical compression or secretion of various locally acting molecules by peri-organ fat 
cells and (ii) lipid accumulation that occurs in non adipose cells including myocytes 
which leads to cardiomyocyte dysfunction or cell death. This is a phenomenon of lipids 
having a toxic effect on the myocardium is known as cardiac lipotoxicity (Wilson et al. 
2007). Research also showed that lipid accumulation in the myocardium may be due to 
the activation of genes involved in cardiomyocyte lipid metabolism (Christoffersen et al. 
2007). The full extent of the effects of obesity on cardiac function has been widely 
researched and published (Wilson et al. 2007; Essop et al. 2009; Du Toit et al. 2008; 
Katakam et al. 2007; Morel et al. 2003; Kenchaiah et al. 2002). These research studies 
have shown evidence of obesity related cardiac dysfunction in experimental animal 
models of obesity.  
 
In these rat models of obesity, it has been shown that the heart muscle contains more 
triglycerides compared to heart muscle from control animals and the obese animals 
display diastolic dysfunction on echocardiographic examination. Obesity is associated 
with eccentric left ventricular hypertrophy, which is associated with left heart dysfunction 
(Opie et al. 2006). 
 
Wistar rats fed a western diet (which comprises 45% of calories from fats) developed 
obesity and consequential cardiac dysfunction after 8-12 months on the diet (Wilson et al. 
2007). However in the same study, cardiac dysfunction was not observed in rats fed on a 
high fat diet (60% calories from fats) nor on a low fat diet (10% calories from fats) 
(Wilson et al. 2007). In a study done on pre-diabetic/obese rats (after being fed a high 
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caloric diet), assessment of mitochondrial function showed diminished ADP 
phosphorylation rates. This damaged mitochondrial function has been shown to be 
associated with cardiac dysfunction during obesity (Essop et al. 2009).  
 
This evidence suggests that the decrease in mitochondrial capacity to produce energy in 
pre-diabetic rat hearts leads to impaired mitochondrial respiratory capacity. This causes a 
reduction in cardiac contractile function and increased cardiac susceptibility to 
ischemia/reperfusion injury in obesity (Essop et al. 2009). 
 
 
1.2.1.4 Obesity and cardiac susceptibility to I/R-injury 
 
Obesity increases myocardial susceptibility to ischemia/reperfusion injury in the isolated 
heart (Du Toit et al. 2007; Katakam et al. 2007; Morel et al. 2003). A study to determine 
the myocardial susceptibility to ischemic-reperfusion injury in a pre-diabetic model of 
diet-induced obesity showed that infarct size was greater in the absence of insulin and 
smaller in the presence of insulin in obese rats (Du Toit et al. 2008). Literature suggests 
that myocardial susceptibility to ischemia/reperfusion injury is associated with metabolic 
changes such as decreased myocardial glucose oxidation during ischemia (Gonsolin et al. 
2007). Obesity thus plays a pivotal role in increased myocardial susceptibility to 
ischemia/reperfusion injury, by means of metabolic changes which leads to insufficient 
capacity of the heart to withstand severe oxygen deprivation (Poirier et al. 2006; 
Dandona et al. 2005; Du Toit et al. 2008). 
 
 
1.2.2 Insulin resistance 
 
Obesity is associated with MS, a syndrome which has already been shown to impact the 
cardiovascular system (Mathieu et al. 2008). Several studies have shown an association 
between obesity and insulin resistance and this largely contributes to the free fatty acid 
supply to the liver. This would then contribute to the development of insulin resistance 
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according to the portal hypothesis for the pathogenesis of insulin resistance (which 
suggests that insulin resistance is caused by increased delivery of free fatty acids (FFA) 
to the liver) (Kobayashi et al. 2001; Mathieu et al. 2008). The mechanism by which 
increased central adiposity causes hepatic
 
insulin resistance is unclear. The "portal 
hypothesis" implicates
 
increased lipolytic activity in the visceral fat and therefore
 
increased delivery of FFA to the liver, ultimately
 
leading to liver insulin resistance (Kabir 
et al. 2005). 
 
Insulin resistance has been described as a state of reduced responsiveness, of insulin 
sensitive tissues, to the physiological concentration of insulin. It is associated with T2DM 
and defective pancreatic β-cell functioning that leads to reduced insulin mediated glucose 
uptake. It has been shown that insulin resistance in aging dog hearts (compared to 
younger activity-matched controls) is associated with disrupted mitochondrial integrity 
and diminished electron transport chain enzyme levels (See review by Sack, 2009).  
 
 
1.2.2.1 Impact of insulin resistance 
 
It is known that the progression from insulin resistance to type II diabetes mellitus is 
brought about by a whole cascade of molecular- and physiological processes (as 
illustrated by figure 2). These processes participate in the insulin signalling pathway and 
involve the phosphorylation and de-phosphorylation of downstream signalling proteins. 
During the state of insulin resistance, the heart continues to rely on fatty acids as its main 
source of energy. The reason is the up-regulation of enzymes involved in fatty acid 
oxidation and down-regulation of glycolytic enzymes, which is promoted by FFA 
stimulation of PPAR alpha (peroxisome proliferator activated receptor- alpha). This 
increased FFA stimulation/uptake/oxidation is only present with concomitant high 
plasma concentrations of free fatty acids which are associated with obesity (Thim et al. 
2006; Hegarty et al. 2009). During ischemia there is a change in energy substrate 
utilization and energy metabolism i.e. a downregulation of fatty acid oxidation and an 
increase in glucose uptake and oxidation (See review by Beadle & Frenneaux, 2010). 
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Fig.2: Etiology of Insulin Resistance and/or Pre-Diabetes. This figure is reproduced from 
Guo & Tabrizchi (2006) 
 
 
Literature suggests that increased fatty acid availability causes increased fatty acid uptake 
and oxidation in the mitochondria and increased expression of mitochondrial uncoupling 
proteins (UCPs). These UCPs are transporters present in the mitochondrial inner 
membrane, which mediate a regulated discharge of the proton gradient generated by the 
electron transport chain (Ledesma, de Lacoba & Rial, 2002). The increased fatty acid 
oxidation and UCP expression decrease the amount of ATP produced per molecule of 
oxygen consumed in the mitochondrial electron transport chain. Therefore the insulin 
resistant heart has an increased oxygen requirement to produce equivalent amounts of 
ATP, a phenomenon known as oxygen wastage (Scheuermann-Freestone et al. 2003; 
Essop & Opie, 2004).  
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Free fatty acid uptake is determined by serum FFA levels. Increased FFA uptake 
increases the FFA concentration inside the mitochondrial matrix and promotes 
mitochondrial fatty acid oxidation (β-oxidation). (See review by Carley & Severson, 
2005). There is a consequent accumulation of certain β-oxidation pathway intermediates 
(Such as ceramides, fatty acyl-CoA and diacyl-glycerol) due to disease induced 
suppression of the catalytic activity of specific enzymes in the β-oxidation pathway (See 
review by Opie & Knuuti, 2009). This is usually present together with increased levels of 
pro-inflammatory cytokines/proteins such as tumor necrosis factor-α (TNF-α), 
interleukin–6 (IL-6) and C-reactive protein (CRP) (See review by Guo & Tabrizchi, 
2006). 
 
As a result, the expression and activity of protein kinase C-θ (PKCθ) increase which 
positively regulates the serine/threonine kinase cascades. Thus the phosphorylation state 
of the insulin receptor substrate (IRS) is changed. The threonine and serine putative 
binding sites are phosphorylated and as a result tyrosine phosphorylation decreases. This 
change in the IRS-phosphorylation state reduces the ability of the IRS to stimulate PI3-
kinase (Phosphatidyl-Inositol-3-phosphate-kinase). The reduced PI3-kinase activity, 
ultimately suppresses the glucose uptake by preventing glucose transporter-4 (GLUT- 4) 
translocation to the cell membrane (myocytes, adipocytes). The end result is type II 
diabetes mellitus or pre-diabetes (Guo & Tabrizchi, 2006; McCarthy et al. 2005). The 
rationale is that this proposed mechanism of insulin resistance might also be true for the 
cardiomyocyte. 
 
 
1.2.2.2 Insulin resistance and cardiac function 
 
Insulin resistance is associated with increased cardiac fatty acid oxidation and a decrease 
in glucose utilization/oxidation (Lee et al. 2005; Aasum et al. 2008; Belke et al. 2000). 
During increased fatty acid oxidation, oxidative phosphorylation is uncoupled from the 
electron transport and the glucose-oxidation is suppressed via inhibition of the glycolytic 
pathway (Hue & Taegtmeyer, 2009). The inhibition of glucose-oxidation leads to the 
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accumulation of lactate and protons within cells. The result is a decrease in the 
intracellular pH (acidosis) which results in: (i) reduced contractile function, (ii) 
exacerbated ischemic injury and, (iii) decreased cardiac mechanical function during 
reperfusion (Dyck et al. 2004; Liu et al. 2002; Kantor et al. 2000; Lee et al. 2005; Hue & 
Taegtmeyer, 2009). Thus it is clear that insulin resistance leads to reduced normoxic and 
reperfusion cardiac mechanical function. 
 
A study that investigated the link between elevated circulating fatty acid concentration, 
the cardiac structure, and cardiac function in obese-insulin resistant rat models found that 
obesity/insulin resistance caused ectopic lipid accumulation in the myocardium, elevated 
circulating fatty acid levels and an increase in triglyceride content of the heart and these 
changes impaired cardiac systolic and diastolic function (Atkinson et al. 2003). The 
myocardial accumulation of fatty acids and metabolites is also associated with cell 
damage, suppression of the sarcoplasmic reticulum (SR) calcium pump function, 
suppression of myofibrillar ATPase activities and decrease in expression of myosin 
heavy chain isoforms (Stanley, Lopaschuk & McCormack, 1997). 
 
In the heart, the
 
two isoforms of the motor protein myosin heavy chain (MyHC) have
 
been shown to be affected by a wide variety of pathological
 
and physiological stimuli. 
Hearts that express the faster MyHC
 
motor protein, , produce more force than those 
expressing the
 
slower MyHC motor protein, ß, leading to the hypothesis
 
that MyHC 
isoforms play a major role in the determination of cardiac
 
contractility. Therefore MyHC 
isoform expression may therefore be important to maintain normal cardiac contractile 
function (Miyata et al. 2000). 
 
During severe ischemia, the protons originating from hydrolysis of glycolytically derived 
ATP is the major contributor to acidosis (Calvani et al. 2000). Within the sarcomere, 
calcium-ions and protons compete for the binding sites on the troponin components of the 
sarcomeric contractile apparatus. This leads to perturbed contraction and thus a reduction 
in the myocardial contractile function (Stanley, Lopaschuk & McCormack, 1997). 
Another adverse effect of the fall in intra-cellular pH (acidosis), especially during 
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ischemia, is an increase in sarcolemmal Na
+
/Ca
2+
 exchange. A large pH gradient is 
created across the cell membrane. Na
+
/Ca
2+
 exchange is activated and increase intra-
cellular Na
+
 levels leads to intra-cellular calcium overload and eventually cell death (Liu 
et al. 2002). Data suggests that Na
+
/Ca
2+
 exchange is not completely inhibited during 
ischemia/hypoxia but rather functions in a "reverse mode" to exchange intracellular Na
+
 
for extracellular Ca
2+
 leading to increased [Ca]i
2+
 (Haigney et al. 1992; Liu et al. 1996a; 
Liu et al. 1996b) 
 
1.2.2.3 Insulin resistance, metabolism and ischemic injury 
 
Many mechanisms contribute to ischemia/reperfusion injury. However, scientific 
evidence suggests that with insulin resistance, contractile dysfunction during and after 
myocardial ischemia is partially mediated by changes in cardiac metabolism. This is 
reflected by severely increased rates of fatty acid oxidation (Lochner et al. 2004). 
Therefore insulin resistance affects cardiac metabolism by impairing glucose uptake and 
oxidation together with a resultant increase in fatty acid oxidation during ischemia (Guo 
& Tabrizchi, 2006). The impaired cardiac metabolism in insulin resistance increases the 
heart‘s susceptibility to ischemia/reperfusion injury (Taegtmeyer, 2000). 
 
Cellular fatty acid concentrations increase 20-30 minutes after induction of ischemia. 
During ischemia and insulin resistance, this increase in cellular fatty acid concentrations, 
elevates fatty acid oxidation and consequently leads to ischemic injury due to enzymatic 
breakdown of membrane phospholipids and accumulation of toxic metabolites from 
increased fatty acid oxidation (Calvani et al. 2000; Opie 2004; Stanley, Lopaschuk, 
McCormack, 1997; Stanley, Recchia, Lopaschuk, 2005; Stanley, 2004). Furthermore, 
indirect evidence has suggested that increased cardiac insulin sensitivity was 
accompanied by increased resistance to ischemia/reperfusion injury (Yue et al. 2005). It 
is important to remember that myocardial ischemia/reperfusion injury, leads to structural 
changes in the myocardium, which is later followed by functional decline due to 
progressive fibrous replacement (See review by Modriansky & Gabrielova, 2009). 
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1.2.3 Dyslipidemia 
 
1.2.3.1 Hypercholesterolemia, coronary artery disease and the myocardium 
 
The typical lipid profile in MS displays dyslipidemia which includes 
hypertriglyceridemia (high levels of triglycerides), hypercholesterolemia or low HDL, 
high LDL and increased plasma fatty acid levels, which is due to increased free fatty acid 
release from the adipose tissue, secondary to insulin resistance (See review by 
Mooradian, 2009). All of the above characteristics are independent risk factors for 
coronary artery disease (CAD) and atherosclerosis. This lipid profile is further aggravated 
by high dietary intakes of saturated- and trans-fatty acids, which also tend to elevate 
blood plasma LDL-levels (Ginsberg et al. 2006; Fortino et al. 2007). 
 
Dyslipidemia plays an important role in the development of artherosclerotic 
cardiovascular disease (ACVD) associated with the metabolic syndrome. There is a 
strong association between elevated LDL levels and the initiation- and progression of 
arterial plaques. Most of the cardiovascular risk associated with the metabolic syndrome 
is mediated by dyslipidemia (See reviews by Cefalu, 2008; Vague, 1956). 
 
A high cholesterol diet has been associated with intracellular lipid accumulation in 
cardiomyocytes and several alterations in the structural and functional properties of the 
myocardium (Puskás et al. 2004). Hypercholesterolemia appears to attenuate the 
cardioprotective effect of ischemic preconditioning via an atherosclerosis independent 
mechanism (Ferdinandy et al. 1998). Recently it was shown that moderate 
hypercholesterolemia combined with a marked hypertriglyceridemia causes moderate 
contractile dysfunction in isolated rat hearts (O´ nody et al. 2003). It also causes marked 
alterations in the expression of genes in functional gene clusters in the myocardium 
(Puskás et al. 2004). These results indicate that hyperlipidemia exerts complex effects on 
the myocardium and negatively affects cardiac function (Csont et al. 2007; O´ nody et al. 
2003).  
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1.2.3.2 Hypercholesterolemia and cardiac metabolism 
 
The lipid accumulation caused by hypercholesterolemia might impair cardiac metabolism 
by promoting the uptake and oxidation of fatty acids and inhibiting glucose oxidation. 
This has been proven by studies which showed that animals fed a high cholesterol diet 
have increased fatty acid oxidation and decreased/inhibited glucose oxidation (Puskás et 
al. 2004; Lopaschuk et al. 2010). Therefore it is clear that hypercholesterolemia 
indirectly affects cardiac metabolism by increasing the circulation/uptake of free fatty 
acids, increasing beta oxidation and inhibiting glucose oxidation (Lopaschuk, Folmes & 
Stanley, 2007; Guo & Tabrizchi, 2006; Lopaschuk et al. 2010). 
 
 
1.2.3.3 Hypercholesterolemia and myocardial susceptibility to I/R-injury 
 
It has now become clear that hypercholesterolemia increases the risk of coronary artery 
disease, which has been associated with reduced tolerance to ischemia/reperfusion injury 
(Puskás et al. 2004, Lopaschuk, Folmes & Stanley, 2007; Lopaschuk et al. 2010). With 
hypercholesterolemia, small LDL particles enter the arterial wall proteoglycans more 
avidly and are extremely susceptible to oxidative modification (Carr & Brunzell, 2004; 
Noh et al. 2006; Franssen et al. 2008). Hyperlipidemia, which includes 
hypercholesterolemia, is often associated with oxidative or nitrosative stress in the 
myocardium and vasculature. Research has shown that when hypercholesterolemia is 
induced with a high cholesterol diet, there is an increase in the formation of reactive 
oxygen species (ROS) as well as peroxynitrite in the rat myocardium. For example, 
peroxynitrite is a product of a reaction between superoxide and nitric oxide (Csont et al. 
2007; Franssen et al. 2008; Mozaffari & Schaffer, 2008). Peroxynitrite has been reported 
to induce DNA damage, increase lipid peroxidation, and to cause post-translational 
modification on proteins (e.g. nitration, oxidation of thiol groups), thereby activating (e.g. 
poly-ADP-ribose polimerase, matrix metalloproteinases) or inhibiting (e.g. aconitase, 
superoxide dismutase) certain enzymes. These cellular effects of peroxynitrite may 
contribute to the development of cardiac contractile dysfunction seen in hyperlipidemic 
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rats, however, the precise mechanisms leading to increased peroxynitrite remain to be 
investigated (Csont et al. 2007). 
 
Therefore hypercholesterolemia is associated with increased production of reactive 
oxygen species (ROS), which is known to be a major contributor to reperfusion induced 
injury. Hypercholesterolemia thus increases myocardial susceptibility to 
ischemia/reperfusion injury, by promoting the formation/production of reactive oxygen 
species (ROS) and decreasing cardiac contractile function (Csont et al. 2007; Franssen et 
al. 2008; Mozaffari & Schaffer, 2008).  
 
 
1.2.4. The impact of MS on mitochondria and mitochondrial function 
 
The mitochondria‘s primary function is the production of energy in the form of ATP. 
This occur during a process called respiration or oxidative phosphorylation which is an 
oxygen dependent process during which the energy substrate (pyruvate) is oxidized to 
acetyl-CoA. Acetyl-CoA enters the citric acid cycle (Krebs cycle), is oxidized to CO2 and 
in the process reducing equivalents (NADH and FADH2) are produced, which are a 
source of electrons for the electron transport chain (ETC) and guanosine tri-phosphate or 
GTP (which is readily converted to ATP) (See review by Gustafsson & Gottlieb, 2008). 
 
It is thus clear that the mitochondria play a very important role in the cardiac energy 
metabolism, also in cardiomyocytes where its importance is displayed by their primary 
function, which is to facilitate oxidative phosphorylation for the generation of ATP 
(Sack, 2009). This is also reflected by the fact that: (i) the heart cell consists of at least 
20% mitochondria by dry weight and furthermore (ii) cardiac muscle tissue has a very 
high mitochondrial content of 23% - 40% of the total volume (Lindenmeyer et al. 1968; 
Bugger & Abel, 2008; Sack, 2009).  
 
Mitochondria do not only produce ATP, but also perform homeostatic functions i.e. 
oxidative metabolism, reactive oxygen species-(ROS) generation, utilization/breakdown 
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and intracellular calcium homeostasis (Sack, 2009). In MS there are profound 
abnormalities in heart mitochondria that lead to mitochondrial dysfunction (Bugger & 
Abel, 2008; Murray et al. 2006; Sharov et al. 1998). 
 
 
1.2.4.1 Mitochondrial dysfunction in obesity 
 
Mitochondrial dysfunction is brought about by uncoupling of mitochondrial respiration 
because of elevated plasma fatty acid levels (as substantiated by evidence pertaining to 
measurements of mitochondrial proton leak) (Sack, 2009). Two paradoxical hypotheses 
exist. The first hypothesis suggests that MS (specifically insulin resistance) causes 
mitochondrial dysfunction and the second hypothesis suggests that mitochondrial 
dysfunction leads to insulin resistance and the metabolic syndrome (Irving & Nair, 2007). 
However, the underlying mechanisms for mitochondrial dysfunction and insulin 
resistance have yet to be fully elucidated. 
 
 
1.2.4.2 Impact of mitochondrial dysfunction 
 
Obese (ob/ob) mice are insulin resistant, leptin deficient and euglycemic (with 
concomitant disruption of circulating glucose, fatty acid concentrations). They exhibit 
diminished glucose oxidation, increased mitochondrial fatty acid oxidation and increased 
mitochondrial oxygen consumption rates (QO2). All these metabolic perturbations lead to 
diminished mitochondrial efficiency (uncoupling) and ultimately result in a reduced 
capacity of the heart to respond to increased cardiac load (Sack, 2009). MS-associated 
mitochondrial dysfunction causes a reduced capacity for energy production. This is 
believed to lead to secondary dysregulation of cellular processes which are important for 
cardiac pump function (including calcium handling and contractile function) and it results 
in an increased energy demand, diminished ATP production and impaired cardiac 
function (Huss & Kelly, 2005). Therefore it has been suggested that mitochondrial 
dysfunction may contribute to the impaired myocardial contractile ability in obese 
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animals. Furthermore it is known that damage to mitochondria can also be as a result of 
ischemia/reperfusion injury i.e. restoration of oxygen flow after a period of ischemia, 
which is known to be associated with an increase in ROS and intracellular calcium levels 
(Modriansky & Gabrielova, 2009; Essop, 2007; Yamada et al. 1994) 
 
Increased plasma levels of non-esterified-fatty acids (NEFAs) in the MS might contribute 
to decreased phosphocreatine/ATP ratios by increasing expression/activity of uncoupling 
proteins (UCPs) (Taegtmeyer et al. 2008; Essop & Opie, 2004). This causes uncoupling 
of the mitochondria and thus mitochondrial dysfunction, which reduces ATP production 
(referring to membrane protective glycolytic ATP) and ultimately reduced cardiac 
contractility (Bugger & Abel, 2008; Sharov et al. 1998, Essop & Opie, 2004). It should 
be noted that mitochondrial UCPs are believed to be expressed as an adaptive 
mechanism/inherent protective mechanism and could have paradoxical functions. These 
functions include the induction of mitochondrial uncoupling and the export of fatty acids 
out of the mitochondria which might reduce cardiac lipotoxicity (Bugger & Abel, 2008; 
Opie & Knuuti, 2009). Another effect of mitochondrial uncoupling is ―oxygen wastage‖, 
since more oxygen is now needed to produce equivalent amounts of ATP (Essop & Opie, 
2004). Furthermore the disruption in the mitochondrial function, associated with obesity, 
exacerbates and accentuates the pathophysiology of diabetes (Sack 2009; Yamada et al. 
1994) 
 
 
1.3 Ischemia and Reperfusion 
1.3.1 Definition of ischemia and reperfusion 
 
Ischemia, whether it is due to a pathological state or not, describes an inadequate blood 
flow/oxygen deprivation which is seen when arterial blood flow through a damaged 
blood vessel is reduced to a volume that does not meet the heart‘s requirements for 
adequate function (Jennings, 1970). Oxygen deprivation leads to certain metabolic 
changes in heart cells such as decreased adenosine triphosphate (ATP) levels, which 
causes a switch from aerobic- to anaerobic metabolism, with a simultaneous 
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accumulation of protons/decrease in intracellular pH (acidosis) (Jennings & Yellon, 
1992). 
 
It is generally agreed that the best treatment for the ischemic myocardium is the re-
establishment of oxygen supply to the affected area as soon as possible. This is achieved 
by reperfusion. However, in addition to the beneficial effects of reperfusion, it can also 
cause further damage such as cell death/necrosis (Piper & Garcia-Dorado, 1999; Jennings 
& Reimer, 1983; Park & Lucchesi, 1999). Even though reperfusion is a paradoxical 
treatment for ischemia associated damage, this remains the only way to salvage 
reversibly damaged tissue. Thus ischemia and reperfusion is linked and is often referred 
to in the literature as ischemia/reperfusion. 
 
During ischemia there is a decrease in blood supply which prohibits the removal of 
possible toxic metabolites. The ATP is insufficient to maintain ion-pump activity which 
causes disturbances in ion homeostasis (Opie, 2004). Damage during ischemia is caused 
by factors such as calcium overload, free radical formation and inflammatory processes 
(Piper & Garcia-Dorado, 1999; Park & Luchessi, 1999; Opie, 2004; Van Vuuren, 2008). 
 
 
1.3.2 Changes in the heart during ischemia and reperfusion 
 
There is a range of changes that occur in the myocardium during ischemia and 
reperfusion. Below is a list of the well documented changes (Ganote & Humphrey, 1985; 
Jennings et al. 1978). 
 
 
Ischemia and reperfusion can lead to: 
 Depletion of energy stores (Jennings et al. 1978) 
 Intracellular acidosis ( Neely et al. 1984; Dyck et al. 2004; Liu et al. 2002) 
 Accumulation of metabolic by-products (Guo & Tabrizchi, 2006; Corr, Gross & 
Sobel, 1984) 
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 Accumulation of intracellular calcium (Clusin et al. 1983; Nayler et al. 1988) 
 Increased cytosolic sodium (Shen & Jennings, 1972; Tani & Neely, 1989) 
 Loss of intracellular potassium (Opie et al. 1969) 
 Mitochondrial damage (swelling, decreased matrix density, partial loss of cristae) 
(Jennings & Ganote, 1976; Schaper et al. 1979) 
 Myofibril relaxation (Jennings & Ganote, 1976; Schaper et al. 1979) 
 Swelling of the sarcoplasmic reticulum (Jennings & Ganote, 1976; Schaper et al. 
1979) 
 
The above mentioned changes lead to decreased cardiac function, decreased 
susceptibility to ischemia/reperfusion injury and decreased cardiac efficiency.  
 
 
1.3.2.1 Overview of cardiac metabolism 
 
In the heart there are two main metabolic pathways for the production of energy in the 
form of ATP, i.e. glycolysis and beta oxidation (Taegtmeyer, 2004). The heart has very 
high energy demands, which is related to the maintenance of cellular processes. These 
processes include: ion-transport, sarcomere function and intra-cellular calcium 
homeostasis (Wilson et al. 2007). Metabolism and the ability of the heart to contract are 
linked. The ATP producing pathways must therefore respond appropriately to the heart‘s 
physiological demands and the delivery of fuel (Taegtmeyer, 2000; Beadle & Frenneaux, 
2010; Macfarlane, Forbes & Walker, 2008).  
 
Glucose is stored in insulin sensitive organs such as the liver in the form of glycogen, by 
a process called glycogenesis. Glucose is transported into cells by glucose transporters 
known as GLUT 4 and GLUT 1 (Guo & Tabrizchi, 2006; Abel et al. 1999). When blood 
glucose is high, the pancreas secretes insulin which promotes GLUT 4 translocation to 
the cell membrane. Glucose is converted to glucose-6-phosphate by an enzyme called 
Hexokinase. From here glucose-6-phosphate is further metabolically modified by a host 
of enzymes in order to form pyruvate, (the end product) and energy in the form of ATP. 
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Pyruvate is oxidized by pyruvate dehydrogenase complex (PDHC) inside the 
mitochondrial matrix. This oxidative mechanism is set in place to degrade carbohydrates 
as a fuel in order to synthesize ATP and this is referred to as glucose oxidation. This 
process is completed in a complex series of steps involving the breakdown/formation of 
ATP, ADP, NAD
+
 and NADPH. All these steps are catalysed by a number of enzymes 
i.e. hexokinase, glucokinase, phosphohexose-isomerase, phospho-fructokinase I, 
aldolase, triphosphate-isomerase, glyceraldehyde-3-P-hydrogenase (G3PDH), phospho-
glyceride-kinase, enolase and pyruvate kinase. See figure 3. 
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Fig. 3: A schematic representation of glycolysis (Depré, Rider & Hue, 1998) 
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Of β-oxidation and glycolysis, an important end product is acetyl-CoA which enters the 
tri-carboxylic acid cycle (TCA-cycle). Here the acetyl-CoA is reduced to reducing 
equivalents NADH and FADH2 which function as carriers/donors of electrons to the 
electron transport chain (ETC). This produces an electro-chemical gradient across the 
mitochondrial membrane that drives ATP synthesis. The electro-chemical gradient is 
produced by pumping protons from the mitochondrial matrix to the intermembranal 
space. The bulk of the protons re-enter the matrix via the F0F1-ATPase (not shown in 
figure 4). However, a proportion of the protons bypass the F0F1-ATPase via the adenine 
nucleotide translocator (ANT) and this is known as the proton leak (ANT is not shown in 
the figure, only the proton leak). The end result of the ETC is the production of ATP in 
the presence of oxygen. See figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: The Electron Transport Chain within the mitochondrion. Illustrated are the 
different complexes and intermediates (Hue & Taegtmeyer, 2009, Essop & Opie, 2004). 
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These metabolic regulatory processes time dependent. This involves regulation at various 
levels: (i) allosteric control of enzyme activity via metabolic intermediates, (ii) signal 
transduction events and (iii) regulation of genes encoding rate limiting enzymes and 
proteins. 
 
The majority of the body‘s lipids are present in the form of triglycerides, free fatty acids, 
phospholipids and cholesterol. In vivo, there are two known sources of fatty acids for 
metabolism: (i) circulating fatty acids bound to plasma albumin which is derived from 
adipose tissue-lipolysis and (ii) fatty acids from the hydrolysis of triglyceride rich 
lipoproteins by an enzyme called lipoprotein-lipase, which is located on the surface of 
endothelial cells in the vasculature (Carley & Severson., 2005).  
 
Triglycerides are broken down into glycerol and fatty acids by the process of lipolysis, 
which is activated during periods of fuel deprivation. The fatty acids are taken up into the 
cardiomyocytes by two transport processes i.e. simple diffusion and protein-mediated-
transport (which accounts for 80% of total fatty acid uptake). The predominant 
sarcolemmal transport proteins are the 88-kDa fatty acid translocase/CD36 (FAT/CD36) 
and a 43-kDa plasma membrane fatty acid binding protein (FABPpm) (Carley & 
Severson, 2005). 
 
Co-enzyme-A (CoA) esters are formed with the fatty acids in the cytosol in order to form 
a compound that is known as fatty acyl-CoA. There are three metabolic pathways that 
contribute to the production of acyl-CoA: (i) oxidation of fatty acids (derived from 
plasma) and the breakdown of intra cellular triacylglycerol, (ii) pyruvate oxidation (that 
originates from lactate dehydrogenase) and (iii) glycolytic activities (Calvani et al. 2000).  
 
Fatty acyl-CoA is transported over the mitochondrial inner membrane after its conversion 
to fatty acyl-carnitine in the cytosol. This chemical reaction is catalysed by carnitine 
palmitoyl transferase-1 (CPT–1). Before the fatty acyl-carnitine is oxidized in the 
mitochondrial matrix, it is converted back to the fatty acid (without the carnitine), by 
carnitine palmitoyl transferase-2 (CPT–2). This enzyme catalyzes the reverse of the 
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reaction CPT- 1 catalyzes. Once the fatty acid is inside the mitochondrial matrix, β-
oxidation occurs and it is further broken down through a number of steps, catalyzed by 
various enzymes. The end product of β-oxidation is acetyl-CoA and ATP (see figure 5). 
 
When a long chain fatty acid such as palmitic acid (which contains 16-carbon atoms) is 
degraded by the β-oxidation pathway, it yields approximately 8 molecules of acetyl-CoA 
or ± 117 molecules of ATP. 
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Fig.5: Overview of the β-oxidation pathway reactions. This figure illustrates the range of 
reactions in the beta oxidation pathway (Lopaschuk et al. 2010). 
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Intracellular control of fatty acid oxidation: 
 
Under normal circumstances, the balance between the utilization/oxidation of the 
different fuels, for the purpose of energy production, is tightly regulated in the heart. The 
selection of fuels solely depends on the heart energy requirements, which is most 
probably determined by the expression of protein coding genes, involved in cardiac 
energy metabolism (Wang et al. 2005). The consumption of fatty acids depends on the 
availabilty of fatty acids to the myocardium and the intracellular control of fatty acid 
uptake/metabolism (Lopaschuk, Folmes & Stanley, 2007). Intracellular control of fatty 
acid oxidation takes place at the level of mitochondrial uptake of fatty acids by carnitine 
palmitoyl transferase-1 (CPT-1). When CPT-1 activity decreases (as would be the case 
during inhibition by malonyl-CoA), then long chain acyl-CoA can be redirected towards 
complex lipid synthesis e.g. triacylglycerol, phospholipids diacylglycerol etc. 
Furthermore, malonyl-CoA is another important inhibitor of fatty acid oxidation in the 
heart (Lopaschuk, Folmes & Stanley, 2007; Beadle & Frenneaux, 2010). 
 
Oxidation of fatty acids is subjected to complex control mechanisms and dependent on a 
range of factors, including: (i) supply of fatty acids to the heart, (ii) presence of 
competing energy substrates such as glucose, lactate, ketones and amino acids, (iii) 
energy demand of the heart, (iv) supply of oxygen to the heart, (v) allosteric control of 
fatty acid uptake, esterification, and mitochondrial transport; and ultimately, (vi) the 
control of mitochondrial function, including direct control of fatty acid oxidation, TCA 
cycle activity, and electron transport chain (ETC) activity (Lopaschuk et al. 2010; Beadle 
& Frenneaux, 2010). 
 
Another important fact to note about fatty acids is that they are ligands for peroxisome 
proliferators-activated receptors (PPARs) and are thus regulators of gene expression. 
Genes that encode for proteins which control myocardial fatty acid uptake and 
metabolism includes PPAR-α, which is regulator of the expression of proteins involved in 
fatty acid uptake and –oxidation (Lopaschuk, Folmes & Stanley, 2007; Guo & Tabrizchi, 
2006).  
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PPAR-α, has been extensively studied, and its target genes are those which encode 
proteins that are involved in: (i) the uptake of fatty acids (FAT/CD36, FATP1), (ii) 
cytosolic fatty acid binding and -esterification (FABPm), (iii) glycerol-3-phosphate 
acyltransferase, diacylglycerol acyltransferase, (iv) malonyl CoA metabolism (MCD), (v) 
fatty acid uptake (CPT 1), (vi) fatty acid oxidation [very-long-chain acyl CoA 
dehydrogenase, long-chain acyl CoA dehydrogenase, medium-chain acyl CoA 
dehydrogenase (MCAD), 3-KAT], (vii) mitochondrial uncoupling [including 
mitochondrial thi-esterases (MTE-1) and uncoupling proteins (UCP2, UCP3)], and (viii) 
glucose oxidation [PDH kinase (PDK) 4] (Lopaschuk et al. 2010). 
 
 
1.3.2.2 Metabolism of the obese heart/insulin resistant heart 
 
As previously mentioned, the state of obesity/insulin resistance, is characterized by 
elevated plasma FFA (free fatty acid) levels which increases FFA uptake, increase 
cellular FFA concentrations and increase beta oxidation (Guo & Tabrizchi, 2006; Aasum 
et al. 2008, Lopaschuk, Folmes & Stanley, 2007). Data suggest that an increased supply 
of free fatty acids negatively influences myocardial function in hearts subjected to 
ischemia/reperfusion (Aasum & Larson, 1997; Lopaschuk et al. 2010; see review by 
Allard, 2004). The negative influence is due to the obesity induced impairment of cardiac 
metabolism by i) increased beta oxidation and ii) intracellular accumulation of potentially 
toxic fatty acid intermediates such as fatty acyl-CoA, fatty acyl carnitine as well as iii) 
the oxygen wasting effect of free fatty acids (Vik-Mo & Mjøs, 1981; Corr, Gross & 
Sobel, 1984). According to Liedtke et al. (1988) excess free fatty acid lead impair 
membrane integrity, organelle sub-performance and myocardial contractility. 
 
In addition, elevated fatty acid levels during obesity/insulin resistance impair glucose 
metabolism, specifically glucose oxidation via inhibition of the pyruvate dehydrogenase 
(PDH) complex. This leads to uncoupling of glycolysis from glucose oxidation 
(Lopaschuk, Wambolt & Barr, 1993; Aasum & Larson, 1997). High fatty acid levels and 
the resultant increased fatty acid-oxidation: (i) strongly inhibits the mitochondrial 
enzyme, pyruvate dehydrogenase, the oxidation of the glycolytic pathway-intermediate, 
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pyruvate, and thus the general inhibition of the whole glycolytic pathway, (ii) uncouples 
oxidative phosphorylation from electron transport (this causes the inefficient use of 
energy stores, especially fatty acids) (Modriansky & Gabrielova, 2009) and (iii) 
consumes more oxygen than glucose metabolism. These adverse effects may result in 
impaired cardiac contractile function and arrhythmias during ischemia (Stanley, 
Lopaschuk & McCormack, 1997). Therefore, there is a definite link between the 
increased rates of β-oxidation and the deleterious effects on the myocardium as a whole, 
in the state of obesity/insulin resistance and during ischemia/reperfusion (Bugger & Abel, 
2008; Lopaschuk, Wambolt & Barr, 1993; Stanley, 2004; Stanley, 2002; Stanley, 
Lopaschuk, McCormack, 1997; Aasum et al. 2008). 
 
From the literature it is clear that the negative effects of elevated free fatty acids are not 
necessarily correlated with their increasing effects the inhibition of potentially toxic fatty 
acid intermediate accumulation. Instead, the negative effects may be related to 
myocardial glucose oxidation/utilization. Therefore it is suggested that an imbalance 
between glycolysis and glucose oxidation could be the possible mechanism of the 
detrimental effects of excess free fatty acid levels (Lopaschuk, Wambolt & Barr, 1993). 
 
Cardiac energy metabolism is regulated by (i) availability of exogenous substrates, (ii) 
hormones such as insulin, (iii) cardiac work/energy demand and (iv) the supply of oxygen 
(Carley & Severson, 2005). Irrespective of whether glucose or fatty acids are used to 
produce ATP, there is a difference in the amount of ATP produced as well as in the 
amount of oxygen consumed. 
 
Fatty acids are less oxygen efficient fuels that consume more oxygen for each ATP 
molecule produced, in comparison to glucose. There is a theoretical 12%-14% increase in 
efficiency of ATP production in shifting from 100% palmitate oxidation to 100% glucose 
oxidation (Wang et al. 2005). Fatty acids may be a more energy efficient fuel (7.3 
ATP=CO2 produced vs. 6.3 ATP=CO2 produced) but glucose is a more oxygen efficient 
fuel (5.5 ATP/O2 consumed vs. 6.3 ATP=O2 consumed) (Wolff et al. 2002). See table 1 
below. Glycolysis can generate ATP in the absence of oxygen, a situation of reduced 
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oxygen availability which resembles ischemia. Thus, theoretically the obese/insulin 
resistant heart should increase glucose oxidation, especially during ischemia. If the heart 
uses glucose as major fuel during ischemia, it will function better. However, the heart 
preferentially oxidizes fatty acids during insulin resistance, which is one of the earliest 
changes that occur after the onset of experimentally induced diabetes/insulin resistance 
(Wang et al. 2005). This choice of fuel by the heart has deleterious effects on the 
myocardium (Lopaschuk, Folmes & Stanley, 2007). The following table displays the 
exact ratios of ATP produced in comparison with oxygen consumed. It clearly highlights 
the fact that the oxidation of glucose uses less oxygen when compared to fatty acids and 
is therefore a better choice of fuel, particularly under anoxic/ischemic conditions. 
 
Table 1: The comparison of complete oxidation of glucose and a fatty acid of equivalent 
carbon chain length (hexanoic acid). The theoretical ATP yields assume perfect coupling 
of substrate oxidation to oxidative phosphorylation of ADP. In this table it is important to 
note the differences in ATP production and oxygen efficiency of glucose and fatty acids 
(hexanoic acid) (Wolff et al. 2002). 
 Glucose 
(C6H12O6) 
 
Hexanoic Acid 
(C6H12O2) 
 
Oxidation 
Equation 
 
C6H12O6 → 6 O2 
6 CO2 → 6H2O 
 
C6H12O2 → 8 O2 
6 CO2 → 6H2O 
 
ATP Yield 38 ATP 44 ATP 
 
Energy 
Efficiency 
6.3 ATP=CO2 
produced 
 
7.3 ATP=CO2 
produced 
 
Oxygen 
Efficiency 
 
5.5 ATP=O2 
consumed 
 
6.3 ATP=O2 
consumed 
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1.3.2.3 Metabolism of the normal/ischemic heart 
 
Carbohydrate metabolism in ischemia: In normal hearts 
 
Ischemia has a biphasic effect on carbohydrate metabolism. Initially glycolysis is 
stimulated and then the glycolytic rate decreases as ischemia becomes more severe and 
then inhibitory metabolites accumulate. During severe ischemia there is an accumulation 
of the products of glycolysis (lactate and protons). This accumulation leads to a decrease 
in the pH (acidosis) which increases acetyl-CoA and NADH levels, inhibits pyruvate 
dehydrogenase (PDH) and ultimately inhibits the glycolytic flux. Therefore, during 
severe ischemia, the lack of washout of the inhibitory metabolites suppresses glycolysis 
(Opie, 1991; Opie & Knuuti, 2009). 
 
 
Fatty acid metabolism during ischemia: In normal hearts 
 
Ischemia inhibits fatty acid metabolism and leads to the accumulation of lipid metabolites 
such as fatty acyl-CoA, diacylglycerol and ceramides (Guo & Tabrichi, 2006; Beadle & 
Frenneaux, 2010). These metabolites inhibit the mitochondrial fatty acid translocase, 
sodium pump and phospholipid cycles. In addition to the inhibited metabolism, 
membrane phospholipids are broken down by the action of phospholipases, which are 
activated by an accumulation of calcium (Opie, 1991; Opie & Knuuti, 2009). 
 
 
1.3.3.4 Metabolism of the obese/ischemic heart 
 
In the obese state, the circulation and uptake of free fatty acids are elevated. However 
there is an imbalance between fatty acid uptake and the rate of fatty acid oxidation which 
is believed to cause accumulation of lipids in the myocardium. In other words, more fatty 
acids are taken up than what is oxidized (Lopaschuk, Wambolt & Barr, 1993; Lopaschuk 
& Barr, 1997; Lopaschuk, 1997; Lopaschuk & Kelly, 2008; Lopaschuk et al. 2010). 
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Lipid accumulation causes myocyte degeneration and cardiac conduction defects (Poirier 
et al. 2006). Thus the lipids that accumulate exert toxic effects on the myocardium; 
known as cardiac lipotoxicity (Opie & Knuuti, 2009). The high rates of fatty acid 
oxidation and the resultant lipid accumulation inhibit glucose oxidation. This results in 
mitochondrial uncoupling and diminished ATP production (Bugger & Abel, 2008). When 
the heart from an obese animal is exposed to ischemic circumstances; the increase in fatty 
acid metabolism predisposes the heart to ischemic damage. The elevation of fatty acid 
oxidation and the inhibition of glucose oxidation have deleterious effects on the obese 
heart during ischemia i.e. reduced contractile function, exacerbated ischemic injury and 
decreased cardiac efficiency during reperfusion (Lopaschuk, Folmes & Stanley, 2007; 
Opie & Knuuti, 2009; Shipp, Opie 1991). 
 
 
1.3.2.5 Signaling pathways and proteins/enzymes involved in metabolism 
 
Overview of key enzymes and proteins 
 
Increased oxidation of fatty acids in obesity/insulin resistance, especially during ischemic 
conditions has harmful effects on the heart. From the literature it is evident that inhibition 
of fatty acid oxidation can be employed to protect the obese/insulin resistant heart during 
ischemia (Opie & Knuuti, 2009). When an inhibitor of fatty acid oxidation is 
administered, the ultimate goal is to inhibit or suppress β-oxidation by inhibiting carnitine 
palmitoyl transferase-1 (CPT- 1), thus preventing acyl moiety uptake and promoting the 
use of glucose as a substrate to produce energy.  
 
The inhibition of β-oxidation of free fatty acids exposes the roles of a variety of key 
enzymes that participate in the β-oxidation pathway i.e. CPT- 1 and medium chain acyl-
CoA-dehydrogenase (MCAD). In addition I will also discuss important proteins i.e. 
insulin receptor substrate-1 (IRS-1) and glucose transporter-4 (GLUT- 4). 
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CPT 1 and MCAD 
 
The transport of long chain fatty acids from the cytosol to the mitochondrial matrix 
destined for β-oxidation is initiated by the conversion of fatty acids to acyl-carnitines by 
CPT-1. This enzyme (i) forms an integral part of the outer mitochondrial membrane, (ii) 
is known to catalyze the rate limiting step in fatty acid oxidation (catalyzes the synthesis 
of long chain acyl-carnitine from length corresponding long chain acyl-CoA) (Calvani et 
al. 2000) and (iii) is furthermore tightly regulated by its physiological inhibitor, malonyl-
CoA (first intermediate in fatty acid synthesis). There are two isoforms of CPT-1 
expressed in mammalian tissue i.e. liver isoform (LCPT-1) and heart/muscle isoform 
(MCPT-1) (Woldegiogis et al. 2000). 
 
Under normal circumstances, ACC (acetyl-CoA carboxylaze) carboxylizes acetyl-CoA 
(from energy substrate oxidation) to form malonyl-CoA, which is a natural inhibitor of 
CPT-1. It is known that CPT-1 is a rate limiting enzyme in the β-oxidation pathway. 
Oxfenicine inhibits CPT-1 and thus the β-oxidation pathway. MCAD (Medium Chain 
Acyl-CoA Dehydrogenase) is also a key enzyme in the β-oxidation pathway and 
therefore the inhibition of CPT-1 will also lead to the inhibition of MCAD (Barger & 
Kelly, 1999). A change in the expression of these proteins would provide valuable 
information regarding the effects of oxfenicine on cardiac energy metabolism in control 
and obese animals, subjected to chronic oxfenicine treatment. See figure 6. 
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Fig.6: CPT-1 portrayed as a rate limiting enzyme and this figures illustrates how it is 
affected by the natural inhibitor malonyl-CoA. 
 
 
IRS -1: 
 
Insulin receptor substrates (IRS-1, -2, -3, and -4) form part of family of docking proteins 
that function as an interface between the insulin receptor and the rest of the insulin 
signalling pathway. IRS-1 is of interest due to the fact that it is the major protein involved 
in the binding and activation of PI3-K (Phospho-Inositol-3-Kinase) (Guo & Tabrizchi, 
2006). IRS-1 is the main site for the development of free fatty acid induced insulin 
resistance (pre-diabetes) due to its inactivation caused by a change in its phosphorylation 
state. In insulin resistant individuals with high circulating levels of free fatty acids, IRS-1 
activity is inhibited due to inappropriate phosphorylation of its phosphorylation sites i.e. 
increase in the phosphorylation of Threonine (Thr) and Serine (Ser) sites and a decrease 
in the phosphorylation of Tyrosine (Tyr) sites (Guo & Tabrizchi, 2006). 
Acetyl-CoA 
Inhibits 
ACC 
Malonyl-CoA 
CPT 1 
& 
Subsequently 
MCAD 
Carboxylates 
Produces 
Oxfenicine 
Inhibits 
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IRS-1 has three putative binding sites (Ser 270, Ser 374 and Ser 641). IRS-1(Ser 641) 
being is known to be highly phosphorylated in a state of obesity/insulin resistance and 
with elevated levels of circulating free fatty acids. This suppresses activation of PI3-
Kinase and consequential GLUT- 4 translocation is lost, which leads to insulin resistance 
and pre-diabetes. Inhibition of β-oxidation (by pharmacological intervention) and the 
resultant increase in glucose oxidation should theoretically promote the IRS-1 (Ser 641) 
phosphorylation (Guo & Tabrizchi, 2006). 
 
 
GLUT- 4: 
 
This protein is the major mechanism of glucose uptake in the mammalian cell (skeletal 
muscle cells & adipocytes). It is directly involved in glucose homeostasis and glucose 
uptake in the heart, in response to the stimulation of the insulin receptor (Guo & 
Tabrizchi, 2006). Under normal conditions, GLUT- 4 resides in intracellular vesicles and 
is translocated to the plasma membrane in response to an insulin signal, exercise and 
ischemia (Murray et al. 2006).  
 
During a state of free fatty acid induced insulin resistance, circulating insulin levels may 
very well be high, but due to erroneous phosphorylation of IRS-1, PI3-K is not activated 
and thus GLUT- 4 translocation to the plasma membrane is perturbed and ultimately 
decreased. The suppression of GLUT- 4 translocation decreases glucose uptake and thus 
elevates blood glucose levels (known as a state of pre-diabetes). 
 
With the GLUT- 4 translocation assessment, a decrease in GLUT- 4 translocation reflects 
a decrease in glucose uptake, as in the case of insulin resistance/obesity (Guo & 
Tabrizchi, 2006). 
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1.3.3 Interventions used to protect the heart against I/R-injury 
 
Interventions that alter cardiac energy metabolism and improve cardiac mechanical 
function should improve myocardial tolerance to ischemia/reperfusion and therefore 
protect against ischemia/reperfusion injury. This is based on previous observations which 
showed that elevated rates of fatty acid oxidation are associated with decreased cardiac 
mechanical function in insulin resistant rats during ischemia/reperfusion. The decrease in 
mechanical function is especially observed during periods of anoxia/ischemia (Hafstad et 
al. 2007). This leads us to believe that elevated rates of fatty acid oxidation during 
ischemia cause this whole cluster of deleterious effects on the heart in obesity. This 
concept is what guided scientists to focus their efforts on compounds that are able to 
“switch” energy substrate utilization away from fatty acid oxidation towards glucose-
oxidation (Hafstad et al. 2007; Taegtmeyer et al. 2005). 
 
Table 2: Methods used to “switch” cardiac metabolism away from fatty acid oxidation 
towards glucose oxidation (Rupp, Zarain-Herzberg & Maisch, 2002).  
 
Direct Approaches Indirect Approaches Alternative Approaches 
Aim: To decrease 
circulating levels of 
fatty acids 
Aim: To increase glucose - 
oxidation 
Aim: To directly inhibit 
fatty acid oxidation 
By Administering (Rx): 
- Glucose-Insulin-
Solutions 
- Nicotinic Acid 
- Beta-Adrenergic 
blocking agents 
By Administering (Rx): 
- Sodium-Dichloro Acetate 
By Administering (Rx): 
CPT-1 Inhibitors 
- Oxfenicine 
- Etomoxir 
- Perhexiline 
- ACCβ 
- Malonyl-CoA 
3-KAT Inhibitors 
- Trimetazidine 
- Ranolazine 
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The aims of these interventions (in Table 2) are to decrease circulating free fatty acid 
levels, increase glucose oxidation and inhibit fatty acid oxidation, respectively. With the 
direct approach, a compound like nicotinic acid has an anti lipolytic effect and suppresses 
circulating fatty acid levels. With the indirect approach, sodium-dichloro acetate inhibits 
pyruvate dehydrogenase kinase (PDHK), activates pyruvate dehydrogenase complex 
(PDHC) and thus increases glucose oxidation. With the alternative approach, compounds 
are used to inhibit different enzymes in the β-oxidation pathway. Enzymes manipulated 
include CPT-1 and 3-KAT or CAT (Keto-Acyl Transferase/Ceto-Acyl Transferase). 
 
 
1.3.3.1 Reperfusion injury salvage kinases (RISK) 
 
Myocardial cells possess prosurvival signaling pathways, which protect the myocardium 
against ischemia/reperfusion-induced injury. These pathways (including the RISK 
pathway) are activated at reperfusion and include proteins such as PI3-K, PKB/Akt, 
P70/S6K and ERK (42/44) (Hausenloy & Yellon, 2004). It would be useful to investigate 
how oxfenicine treatment before an ischemic event, influences the RISK pathway activity 
or whether the RISK pathway is at all involved in the oxfenicine induced cardiac effects.  
 
The MAPK kinase family (or mitogen-activated serine/threonine kinases) is comprise of 
extracellular activated signal-regulated kinase (ERK), p38 MAP kinase, and c-Jun N-
terminal kinase (JNK) (Kennedy et al. 2000). Also, various trophic factors (i.e., insulin-
like growth factor-1) activate protein kinase-B (PKB) (Cicconi et al. 2003). The RISK 
pathway, especially ERK and PKB, is activated during reperfusion. This is an anti-
apoptotic pathway and thus confers cardioprotection against ischemia/reperfusion injury 
when activated (Hausenloy & Yellon, 2004). 
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1.3.3.2 Glucose-Insulin-Potassium solutions (GIK) 
 
The benefits of enhanced glucose provision by means of GIK administration include 
increased energy production, reduced loss of K
+
- ions, inhibition of changes in the 
membrane action potential, altered extracellular volume and decreased circulating levels 
of free fatty acids. The above mentioned benefits cause a reduced incidence of 
arrhythmias, reduced ischemic contracture and improved recovery of cardiac function 
(King & Opie, 1998). It has been shown that glucose and/or insulin protects the isolated 
rat heart from fatty acid-induced ischemic damage, when it is present from the start of 
coronary ligation (Apstein & Opie, 2005; Lopaschuk et al. 2010). 
 
 
1.3.3.3 Dichloro Acetate (DCA) 
 
DCA treatment is one approach to prevent lactate accumulation in the myocardium from 
obese animals (Wolff et al. 2002; Clarke, Wyatt & McCormack, 1996). DCA promotes 
myocardial glucose oxidation at the expense of myocardial fatty acid oxidation and 
appears to be relevant in the therapeutic management of angina pectoris (Lopaschuk et al. 
2010). 
 
 
1.3.3.4 Interventions aimed at decreasing/inhibiting FFA metabolism 
 
The aim of this approach is to promote the increase of glucose-oxidation by directly 
inhibiting or suppressing fatty acid oxidation. Recent studies have indicated that the 
manipulation of myocardial metabolism may be a valuable tool in the improvement of 
functional outcomes of patho-physiological/stressful conditions such as an ischemic 
insult (Aasum, Hafstad & Larson, 2003). 
 
The increase in glucose oxidation and lactate uptake/metabolism is achieved by (i) 
decreasing citrate levels and the inhibition of phospho-fruckto-kinase (PFK) and lastly 
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also by (ii) lowering acetyl-CoA and/or NADH levels in the mitochondrial matrix, 
thereby lowering the inhibition of pyruvate dehydrogenase complex (PDHC) (Aasum, 
Hafstad & Larson, 2003; Lopaschuk et al. 2010). 
 
In the laboratory and clinical setting the inhibition of fatty acid oxidation can be achieved 
by a number of chemical compounds, which achieve their effect by acting on various 
enzymes within the β-oxidation pathway. These include: carnitine palmitoyl transferase-I 
(CPT-1), which is partially inhibited by oxfenicine (4-hydroxy-L-phenylglycine) (Rupp, 
Zarain-Herzberg & Maisch, 2002). 
 
Research interest in oxfenicine started in the early 1980‘s when it was found to be 
effective in decreasing chest pain in patients with obstructive coronary artery disease and 
stable angina. Oxfenicine also protected hearts from necrotic tissue damage during 
ischemia (Stephens, Higgins & Harris, 1985). 
 
4-Hydroxy-L-phenylglycine is transaminated in the heart and liver to 4-hydroxy-phenyl-
glyoxylate (HPG), which acts at the level of CPT-1. It therefore inhibits palmitoyl 
carnitine formation from palmitate (Stephens, Higgins & Harris, 1985). It achieves its 
inhibitory effect by its intermediate 4-hydroxy-phenyl-glyoxylate (HPG) and does this in 
a pH dependent manner, analogous to malonyl-CoA (Korb et al. 1984; Stephens, Higgins 
& Harris, 1985). This leads to a decrease in NADH/NAD
+
 and Acyl-CoA/CoA ratios, 
causing secondary activation of pyruvate dehydrogenase with resultant stimulation of 
glucose utilization (Higgins, Morville & Burges, 1981).  
 
There are, to date, only two mechanisms that have been identified by which oxfenicine 
induced inhibition of fatty acid oxidation is achieved i.e. (i) by greater sensitivity of heart 
CPT-1, than liver CPT-1 to HPG inhibition and (ii) by greater oxfenicine 
aminotransferase activity in heart than in the liver (Stephens, Higgins & Harris, 1985).  
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Fig.7: Schematic representation of the proposed mode of action of CPT-1 in the heart of 
obese animals 
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1.4 Hypothesis & Aims 
 
We hypothesize that chronic oxfenicine (4-Hydroxy-L-phenylglycine) treatment of obese 
animals may improve cardiac mechanical function and myocardial tolerance to 
ischemia/reperfusion injury. 
 
To test this hypothesis we aim to investigate the effects of chronic oxfenicine treatment 
on: 
 
1. Basal cardiac mechanical function  
2. Myocardial tolerance to ischemia/reperfusion as assessed by documenting 
reperfusion function and myocardial infarct size  
3. Mitochondrial respiration in isolated mitochondria 
4. The RISK pathway function and activity (ERK42/44 and PKB/Akt)  
5. CPT-I, MCAD and GLUT- 4 expression and IRS-1 activation. 
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CHAPTER 2 
MATERIAL AND METHODS 
 
2.1 Experimental groups 
 
For this study, male Wistar rats were used. Rats were housed in the University of 
Stellenbosch Central Research Facility, under optimal conditions i.e. constant 
temperature (22°C) and humidity (40%). Throughout the study, the South African 
Medical Research Council‘s Guide for Humane Use of Laboratory Animals was 
followed. Ethical clearance was obtained from the Committee for Experimental Animal 
Research (CEAR) of the Faculty of Health Sciences, University of Stellenbosch. Ethical 
clearance number P08/02/002. When the rats reached a weight of 200±5 grams they were 
randomly divided into a control- and an experimental diet fed (DIO) groups. 
 
Groups for the different experiments were: 
 
Heart perfusion experiments: 
For this series of experiments we had four experimental groups (10 rats per group): 
Control group, DIO group, control + oxfenicine, DIO + oxfenicine.  
 
Infarct size determination experiments: 
For this series of experiments we had four experimental groups (10 rats per group): 
Control group, DIO group, control + oxfenicine, DIO + oxfenicine.  
 
Western blot analysis experiments: 
For this series of experiments we had four experimental groups (6 rats per group): 
Control group, DIO group, control + oxfenicine, DIO + oxfenicine.  
 
Mitochondrial function experiments: 
This division yielded four experimental groups (6 rats per group): Control group, DIO 
group, control + oxfenicine, DIO + oxfenicine. Glutamate experiments were done in 
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duplicate. Palmitate experiments were performed using 3 rats per group and not in 
duplicate. 
 
 
2.2 Rat diets used 
 
The standard rat chow diet (SRC- diet) consisted of: 60% carbohydrate, 30% protein and 
10% fat. The high caloric diet (HCD) consisted of: 65% carbohydrate, 19% protein, 16% 
fat. The control rats were fed a standard rat chow diet, while the DIO group received a 
high caloric diet (Pickavance et al. 1999). The feeding program continued for a period of 
16 weeks. The food consumption was measured daily but animals were allowed to feed 
ad libitum. The average daily energy consumption for the SRC and HCD fed animals 
were as follows: 
 
Energy consumption: SRC- diet  HC- diet 
Food consumption (FC) 29g/day 57g/day 
Energy consumption (EC) 13.1kJ/g 10.1kJ/g 
Energy consumption/day 379.9kJ 575.7kJ 
 
2.3 Drug administration: 
 
Oxfenicine (Aldrich Sigma Chemicals) was administered in the drinking water at a 
dosage of 200mg/kg/day (Okere et al. 2007). This drug supplementation was initiated 
from the beginning of week 9 of the feeding program. Rats were allowed to drink/eat ad 
libitum.  Therefore, in order to calculate the correct dose of drug in the water in relation 
to the animals‘ increased bodyweights and water consumption, we calculated the average 
bodyweights and water consumption per group weekly. The drug concentration in the 
water was then determined for the average bodyweight for the animals, taking into 
consideration the amount of water they drank.   
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Calculation of oxfenicine dose in 2 litres to obtain 200mg oxfenicine/kg/day: 
Dose (g/2L) = [(200mg (dose) x Aveweight (kg)) x 2000 (ml)/Avewater consumption (ml)]/1000 
 
2.4. Experimental protocols 
 
2.4.1 Experimental protocol - Part 1 
 
The rats were on the diet for 16 weeks and oxfenicine given to SRC and HCD fed 
animals for the last 8 weeks of the feeding regime. After that, the animals were sacrificed 
and a range of experiments were performed. The first series of animals were used to 
determine body weights and to collect retro peritoneal (RP) fat which was weighed to get 
the RP weights. This same series of rat hearts were excised and used for the assessment 
of mitochondrial respiration with the oxygraph. A second series of rats were perfused on 
the Langendorff perfusion system and used to determine cardiac mechanical function 
after 40 minutes of regional ischemia and infarct size were determined after two hours of 
reperfusion. The heart parameters (heart rate and left ventricular developing pressure) 
were measured during stabilization and during reperfusion. The average of these 
measurements was used to calculate the percentage cardiac functional recovery during 
reperfusion, after which infarct size was determined using TTC staining (this procedure is 
explained in the section 2.5.2. of experimental procedures). For further reference, see 
figure 1 below. 
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Fig. 1: Outline of the steps followed for the measurement of body weights, retro-
peritoneal fat weights, assessment of mitochondrial respiration and measurement of 
mechanical function as well as the determination of infarct size. 
 
 
2.4.2 Experimental protocol - Part 2 
 
A third series of rats were used to determine cardiac mechanical function on the 
Langendorff perfusion system, after 25 minutes of global ischemia and these hearts were 
Protocol for Langendorff perfusions and 
infarct size determination 
 
Biometric data 
1. Body weights 
2. RP weights 
3. Mitochondrial work 
4.  
Hearts collected 
4. Infarct size 
Stabilization 
30 minutes 
Regional ischemia 
40 minutes 
Reperfusion 
2 hours 
TTC staining 
5. Heart parameters were recorded at 10 minute 
intervals as indicated by the arrows 
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freeze clamped after 30 minutes of reperfusion for Western blot analysis (this procedure 
is explained in the section 2.5.4. of experimental procedures). The heart parameters 
(heart rate and left ventricular developing pressure) were measured during stabilization 
and during reperfusion. These measurements were used to calculate the percentage 
cardiac functional recovery. For a detailed outline, see figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Outline of the steps followed for the measurement mechanical function and 
myocardial sample collection for western blot analysis. 
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2.5 Experimental procedures 
 
2.5.1 Langendorff rat heart perfusion 
 
The rats were euthanized with an intraperitoneal injection of sodium pentobarbitone 
(injected 0.4ml/0.5kg ~ 160mg/kg). A thoractomy was performed and the hearts were 
excised. The hearts were then placed in ice cold Krebs Henseleit buffer. Composition of 
the KH buffer solution: 118.46mM NaCl, 24.995mM NaHCO
-
3, 4.748mM KCL, 
1.185mM KH2PO
-
4, 1.19mM MgSO4.7H2O, 1.25mM CaCl2.2H2O (11mmol glucose, 
1.2mmol palmitate and 30μIU/mℓ insulin). The rat hearts were mounted on the 
Langendorff perfusion system and perfused for a stabilization period of 30 minutes. A 
balloon was inserted into the left ventricle. This balloon was connected to a computerized 
data acquisition system [Gentronics chart recorder, version 1.00, Tygerberg, South 
Africa] which recorded the left ventricular systolic, left ventricular diastolic pressure, left 
ventricular developing pressure (LVDP) and heart rate (HR). These functional parameters 
were used to determine the rate pressure product (RPP = HR x LVDP) which is an index 
of mechanical heart function. In order to obtain the cardiac functional recovery, the RPP 
after ischemia was devided by the RPP before ischemia times by 100%.  
 
 
2.5.2 Infarct size determination 
 
The infarct size determination was only done on the hearts that were subjected to 40 
minutes of regional ischemia and 2 hours reperfusion. 
 
After the heart was excised and mounted on the Langendorff perfusion apparatus. All 
hearts were then allowed to stabilize for at least 30 minutes. The proximal portion of the 
left anterior descending (LAD) coronary artery was first localized between the left atrial 
appendage and the right ventricular outflow tract. The coronary artery was 
ligated/occluded using a 6-0 polypropylene suture around the major trunk of the LAD 
coronary artery or its prominent branches. The ends of the thread were passed through a 
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small piece of PE50 tube to form a snare. Ischemia was induced by pulling the snare tight 
and then fixing it by clamping the tubing with a small hemostat. This achieved coronary 
artery occlusion. Ischemia was confirmed by regional cyanosis, a substantial decrease in 
left ventricular developed pressure (LVDP) and a 40% fall in coronary flow. Ischemia 
was induced for 40 minutes. Reperfusion was initiated by releasing the snare and thus 
opening the occluded coronary artery. Hearts developing ventricular fibrillation (VF) 
usually spontaneously reverted to sinus rhythm. VF lasting more than 45 sec was treated 
with finger flick cardioversion until a normal sinus rhythm was obtained. No 
pharmacological agents were used for defibrillation. The hearts were then reperfused for 
two hours after which the silk suture was securely tied around the coronary artery and 
0.5% Evans blue solution (5mℓ) was slowly infused via the aorta in order to stain the 
hearts. The hearts were then placed in a freezer and frozen overnight. 
 
Hearts were then cut into ± 2mm slices. One heart yields about 5 slices that were then 
stained by incubation in 1% w/v 2, 3, 5 – triphenyl tetrazolium chloride salt (TTC). 
Principle of this procedure: The damaged myocardial cells in the infarcted area release an 
enzyme. TTC binds to this enzyme and causes a red/pink colour to develop. Finally, 
formaldehyde is added to stop all chemical reactions. The viable area has a blue colour, 
the infarcted area a white colour and the area at risk has a red/pink colour. The infarct 
size were determined by planemetry and expressed as a % of the area at risk. During 
planemetry, the different areas are traced with an ink marker pen onto a transparent sheet, 
supported by a perspex board. The transparent sheet was then scanned in and a computer 
program (UTHSCSA Image Tool) was used to determine the infarct size, expressed as a 
% of the area at risk. 
 
 
2.5.3 Isolation of mitochondria 
 
Hearts were excised from respective experimental groups (Controls, DIO, Control + 
oxfen and DIO + oxfen). The atria were cut off and the hearts were placed in tubes 
containing 5°C KE isolation medium which consisted of: 0.18M KCL, 0.001M EDTA 
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and 2M Tris to achieve pH-7.4. While in the KE isolation medium the hearts were cut in 
small pieces and washed 4-5 times with isolation medium to remove all traces of blood. 
The sample was homogenized using a polytron tissue homogenizer for 2 times 4 seconds 
at a speed of 4. This was done on ice. The sample was then centrifuged for 10 minutes at 
755 x g (2500rpm). The pellet (containing fat and cellular debris) was separated from the 
supernatant and the supernatant was centrifuged for 10 minutes at 18800 x g (12500rpm). 
The supernatant was now decanted and this time the pellet (containing the mitochondria) 
was loosened from the bottom of the tube and resuspended in 500µl of KE isolation 
medium. The resuspended pellet was pipetted into a glass teflon homogenizer (Potter 
Elvehjem) and partly homogenized. The refined pellet is pipetted into an Eppendorff; this 
contained the isolated mitochondria and was placed on ice. From this suspension of 
isolated mitochondria, 50µl was pipetted in 1ml of 1% TCA for later mitochondrial 
protein determination using the Lowry method (Lowry et al. 1951). The rest of the 
isolated mitochondria were used for the oxygraph experiments (Lanza & Nair, 2009; 
Lindenmeyer, Sordahl & Schwartz, 1968). 
 
 
2.5.3.1 Assessment of mitochondrial function: Isolated mitochondria 
 
For the purpose of oxygraph experiments the mitochondria were isolated from fresh rat 
heart tissue. 600µl Incubation medium (which contained 1.25M Sucrose, 100mM Tris-
HCl, 85mM K2HPO4, 50mM Glutamate or Palmitoyl-L-Carnitine, 20mM Malate) was 
added in the cell of the oxygraph (Hansatech Instruments (2006) version 2.1). Prior to 
experiments the oxygraph was calibrated. The calibration procedure was as follows: The 
electrode of the oxygraph was cleaned with rapid electrode disc polish and a cotton bud. 
A drop of 50% KCl was placed on the electrode and a small piece of each of the 
membrane and cigarette paper (Rizla quality papers) was placed on the drop of KCl. The 
membrane and cigarette paper was tightly set in place by using an O-ring and a plunger. 
The excess membrane and cigarette paper was cut off and the larger black rubber ring 
was set in place around the electrode. The oxygraph cell chamber was closed by turning 
the outside cover of the cell. Water was placed in the cell chamber with a pipette (600µl). 
 50 
This chamber was connected to a water bath with the temperature set to 25°C. The water 
(600µl) in the chamber was removed and 600µl of incubation medium was pipetted into 
the cell. The computer features are activated (stirrer speed, graph zoom and axes & 
temperature). A signal was recorded on the computer screen and once a signal plateau 
was reached, Na2S2O4 (oxygen scavenger) was added. Once the oxygen signal was zero 
the calibration was completed and saved. The cell chamber was washed with distilled 
water. This washing step was repeated 4-5 times. After this, 600µl of incubation medium 
was pipetted into the cell and allowed to reach 25°C. Once the desired temperature was 
reached, the experiment was started by pressing ―go‖ and a straight line (signal) was 
observed and allowed to run for 1 minute. 
 
The mitochondria (100µl) were pipetted into the cell of the oxygraph and once an active 
mitochondrial respiring state was confirmed, 50µl of 1mM ADP is added and state 3 
respiration (ADP converted to ATP) was recorded on a connected computer (PC). The 
last state, referred to as state 4 respiration (substrate being used up and about to reach 
plateau), was then recorded after a few seconds. Thereafter, 100µl of 25mM ADP was 
added and the cell of the oxygraph is closed in order to induce a state of anoxia (25 
minutes). After anoxia, the mitochondria were re-oxygenated and the recovery of state 3 
was recorded and calculated. During the progress of the experiment, different endpoints 
were investigated i.e. ADP/O (ADP to oxygen ratio), RCI (respiratory control index), 
QO2 (rate of oxygen consumption) as well as the percentage recovery of state 3 
(Lindenmeyer, Sordahl & Schwartz, 1968).  
 
2.5.3.2. Calculation of mitochondrial respiratory parameters: 
 
1. ADP: O ratio = nmoles ADP / total O2 uptake (state 3) 
2. RCI = Rate of oxygen uptake (state 3) / Rate of oxygen uptake (state 4) 
3. QO2 = Oxygen uptake/mg mitochondrial protein 
4. ADP phosphorylation rate = nmoles ADP/1 minute/mg mitochondrial protein 
5. % Recovery of state 3 = state 3 (after re-oxygenation) / state 3 (before anoxia) x 
100 
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2.5.3.3. Lowry protein determination protocol: to determine mitochondrial proteins 
 
Preparation of the Lowry: 
 
We took 50µl of the mitochondria suspension and added 1ml 10% TCA. This was 
allowed to stand on ice for at least 3 minutes or over night in the fridge/cold room. Then 
the sample was centrifuged at 250rpm for 15 minutes. The supernatant was decanted and 
500µl NaOH (1N) was added. This mixture was heated in a water bath at 70°C in order to 
denature the proteins. The sample was vortexed and 500µl H2O was added and 
thoroughly vortexed. After these steps the sample was ready for protein determination. 
50µl of the sample and appropriate standards were placed in Lucham tubes and 50µl 
0.5N NaOH was added in another tube (blank) [experiment was done in triplicate]. 
Thereafter 1ml NaK-tartrate-CuSO4 was added in every tube with time intervals of 10 
seconds. Each tube was vortexed after every addition. After ten minutes (measured from 
the first addition) 100µl Folin-C was added with the same time intervals of 10 seconds. 
After the addition of Folin-C, the contents of the tubes changed colour. After 30 minutes 
the optical density was read at 750nm against the blank.  
 
 
2.5.4 Western blot analysis 
 
Hearts used for western blot protein analysis 
 
A separate series of animals were prepared for tissue sample collection. The hearts were 
excised and placed in a container with ~ 4°C of Krebs Henseleit solution. Within ~ 1 
minute the heart was mounted on the perfusion apparatus via the aortic cannula. The 
heart was retrogradely perfused for 30 minutes then subjected to 25 minutes of global 
ischemia and 30 minutes of reperfusion. On completion of these perfusions, the hearts 
were freeze clamped with Wollenburger tongs, pre- cooled in liquid nitrogen and stored 
at -80°C. 
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A general Western blot protocol 
 
Myocardial tissue was collected as described above. Lysates were made from the hearts 
and added to tubes containing 700μℓ of the lysis buffer. The hearts was then 
homogenized (using a Polytrol homogenizer) in lysis buffer. The contents of this buffer 
were: 20mM, Tris-HCL (pH- 7.5), 1mM EGTA, 1mM EDTA, 150mM sodium chloride 
(NaCl), 1mM β-glycerophosphate, 2.5mM tetrasodiumpyrophosphate, 10mM sodium 
vanadate (NaVO3), 100mM phenylmethylsulphonylfluoride (PMSF), 10 μg/mℓ leupeptin, 
10μg/mℓ aprotonin, 1% Triton X-100. After homogenization, the samples were 
centrifuged at 1000g for 10 minutes. The supernatant was then separated from the pellet, 
the pellet was decanted and the supernatant was used for further experimentation.  
 
Protein extraction: 
 
A Bradford protein determination assay (Bradford, 1976) was done. Microsoft Office 
Excel was used to draw a standard curve. From this curve the protein content (μg) of each 
of the samples was determined. The samples were diluted with lysis buffer into a final 
protein concentration that was equal in amount and volume. A final mixture was made of 
sample and Laemmli sample buffer in a 2:1 ratio. 
 
Protein separation: 
 
The sample (consisting of the heart in lysis buffer and Laemmli sample buffer) was 
boiled for 5 minutes and stored at -20°C. The same amount (μg) of protein (depending on 
the protein of interest) in the same volume (μℓ) of lysate was loaded onto a sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS – PAGE) gel (the % gel 
differs from experiment to experiment). 
 
The samples were loaded in a 4% stacking polyacrylamide gel and separated on gels 
ranging from 7.5%-12% (depending on the protein of interest). The gels were allowed to 
run (using the standard Bio-Rad Mini-Protean II System) and proteins were transferred to 
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a polyvinylidene fluoride (PVDF) membrane (Immobilon ™ P, Millipore). This transfer 
process was done in a tank electro transfer set up. In this tank, the membrane-gel stack is 
immersed in transfer buffer, through which an electrical current is applied. This buffer 
contained: 25mM Tris, 192mM Glycine and 20% Methanol. Equal loading was verified 
by Ponceau‘s red staining and Beta-tubulin.  
 
Table 3: Details for proteins that were investigated by western blot analysis: protein 
name, type, size, casting gel, stacing gel and loading volume. 
 
Protein Size Type Casting gel Stackin
g gel 
Load (µl) 
CPT-1 75 kDa H-20-rabbit 
polyclonal antibody 
10% 4% 9µl 
(60µg/prot) 
IRS-1 180 kDa Ser 641-rabbit 
polyclonal antibody 
8% 4% 9µl 
(80µg/prot) 
MCAD 45 kDa F-15-goat polyclonal 
antibody 
12% 4% 9µl 
(60µg/prot) 
ERK 42/44 42/44 kDa Thr202/Tyr204-
rabbit polyclonal 
antibody 
12% 4% 9µl 
(60µg/prot) 
PKB/Akt 60 kDa Ser473-rabbit 
polyclonal antibody 
10% 4% 9µl 
(50µg/prot) 
GLUT-4 55 kDa H-61-rabbit 
polyclonal antibody 
10% 4% 9µl 
(50µg/prot) 
Beta 
Tubulin 
55kDa rabbit polyclonal 
antibody 
10% 4% 9µl (50-
80µg/prot) 
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Blocking of membranes/secondary antibody: 
 
The membranes were blocked with 5% fat free milk for 2 hours and washed with 0.1 % 
TBS–Tween. The primary antibody was diluted (1:1000) in TBS – Tween/milk and 
allowed to bind to the membrane over night (or at least 5 hours). The following morning, 
the membranes were washed with 0.1 % TBS–Tween and the secondary antibody was 
added (at room temperature) for an hour. Secondary antibody was an ECL anti-rabbit (or 
anti-goat depending on the primary antibody) immunoglobulin G, Horseradish 
peroxidase-linked (from donkey) secondary antibody (Amersham), diluted in TBS-
Tween (milk) solution (1:4000). After an hour, the excess/unbound secondary antibody 
was washed off and the membrane was covered with ECL™ detection reagents for 1 
minute, then exposed to an autoradiography film (Hyper film ECL, RPN 2103). Specific 
signals were detected by Chemiluminescence and captured on the radiography film. 
Finally the reaction was quantified by laser densitometry (UNSCAN – IT™ version 5.1, 
Silk science). For comparison between groups, samples from negative control hearts were 
included in each blot and used for normalization of the unknown samples (i.e. calculation 
of the ratio between the sample and negative control). Data is expressed in arbitrary units 
(AU). 
 
 
2.6 Statistical Analysis 
 
A two way ANOVA was done, followed by a Bonferroni post hoc test. A t-test or a one 
way ANOVA was done where applicable. A p < 0.05 was seen as statistically 
significantly different. All the results are expressed as the mean ± SEM. 
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CHAPTER 3 
RESULTS 
 
3.1 Biometric-, functional- and infarct size data after 16 weeks on the feeding 
program 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.1: The body weights of 16 week control- and high caloric diet fed (DIO) rats, 
with and without oxfenicine treatment. All values are expressed as the mean ± SEM. 
Sample size (n) = 10. *P< 0.0004 and #P< 0.0001. 
 
 
This data showed that there were significantly higher body weights in DIO group vs. 
control group (511.30 ± 10.86g vs. 440.50 ± 8.07g). This is a clear indication that the 
high caloric diet did have an effect on the body weights. The DIO + oxfen group also had 
significantly higher body weights than control + oxfen group (514.80 ± 7.73g vs. 427.30 
± 6.61g).  
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Fig. 3.1.2: The retro peritoneal fat weights of 16 week control- and high caloric diet fed 
(DIO) rats, with and without oxfenicine treatment. All values are expressed as the mean ± 
SEM. Sample size (n) = 10. *P< 0.0001, #P< 0.0004.  
 
 
The RP fat weights without treatment were significantly higher in the DIO vs. Controls 
(33.98 ± 1.93g vs. 20.37 ± 1.06g). It is clear that the diet did have an effect on the IP fat 
weights of the animals. The RP weights of the DIO + oxfen are also higher than that of 
the controls + oxfen (36.73 ± 1.84g vs. 22.67 ± 1.96g).  
 
 
 
 
 
 
 
 
 
# 
* 
C
on
tr
ol
D
IO
0
10
20
30
40
50
Vehicle
Plus Oxfenicine
Groups
W
e
ig
h
t 
(g
)
 57 
C
on
tr
ol
D
IO
0
10000
20000
30000
40000
Vehicle
Plus Oxfen
Groups
R
P
P
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.3: Basal cardiac function (RPP) of the different groups, with and without 
oxfenicine treatment. All values are expressed as the mean ± SEM. Sample size (n) = 10. 
P> 0.05 
 
 
There were no differences in the basal cardiac mechanical function (before regional 
ischemia) between the control group vs. DIO group (27839± 3417 RPP vs. 27811± 2715 
RPP). Comparing for differences within groups that were treated with oxfenicine i.e. 
control vs. control + oxfen (27839± 3417 RPP vs. 21100± 3277 RPP) and diet vs. DIO + 
oxfen (27811± 2715 RPP vs. 23754± 2807 RPP) data showed no significant differences 
in function. Thus neither the drug nor the diet had an effect on either group.  
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Fig.3.1.4: Cardiac functional recovery, after 40 minutes of regional ischemia and 10 
minutes of reperfusion, with and without oxfenicine treatment in the respective groups. 
All values are expressed as the mean ± SEM. Sample size (n) = 10. *P< 0.001, #P< 
0.001, $P< 0.0019.  
 
 
The functional recovery was higher in the control group vs. control + oxfen (71.57± 
4.03% vs. 26.05 ± 2.36%). There was a significantly better functional recovery in the 
control rats vs. DIO groups (71.57 ± 4.03% vs. 38.01 ± 8.33%). Recovery was improved 
in the DIO + oxfen vs. DIO groups (71.46 ± 4.27% vs. 38.01 ± 8.33%). There was a 
marked decrease in the mechanical function, after ten minutes reperfusion in the control 
groups treated with oxfenicine. These results suggest that chronic oxfenicine treatment 
improves cardiac mechanical function in the DIO rats and controversially, decrease 
functional recovery of the control rats. 
 
 
# 
* 
$ 
C
on
tr
ol
D
IO
0
20
40
60
80
Vehicle
Plus Oxfen
Group
P
e
rc
e
n
ta
g
e
 R
e
c
o
v
e
ry
 (
%
)
 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.1.5: Cardiac functional recovery, after 40 minutes of regional ischemia and 20 
minutes of reperfusion, with and without oxfenicine treatment in the respective groups. 
All values are expressed as the mean ± SEM. Sample size (n) = 10. *P< 0.001, #P< 
0.001, $P< 0.001.  
 
 
The functional recovery was increases in the control vs. control + oxfen (70.43 ± 3.58% 
vs. 25.93 ± 2.61%). There was a significantly better functional recovery seen in the 
control rats vs. DIO groups (70.43 ± 3.58% vs. 34.83 ± 9.07%). Recovery was improved 
in the DIO + oxfen vs. DIO groups (70.40 ± 4.20% vs. 34.83 ± 9.07%). The overall effect 
of chronic oxfenicine treatment on cardiac mechanical function indicates that the drug 
has deleterious effects on control hearts and protective effects on DIO hearts.  
 
 
 
 
 
# 
* 
$ 
C
on
tr
ol
D
IO
0
20
40
60
80
Vehicle
Plus Oxfen
Groups
P
e
rc
e
n
ta
g
e
 R
e
c
o
v
e
ry
 (
%
)
 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.1.6: Cardiac functional recovery, after 25 minutes of global ischemia and 10 
minutes of reperfusion, with and without oxfenicine treatment in the respective groups. 
All values are expressed as the mean ± SEM. Sample size (n) = 10. *P< 0.0025, #P< 
0.0001, $P< 0.0011.  
 
The functional recovery was increased in the control vs. control + oxfen (86.02 ± 3.01% 
vs. 47.63 ±9.07%). There was a significantly improved functional recovery seen in the 
control rats vs. DIO groups (86.02 ± 3.01% vs. 53.79 ±1.67%). Recovery was increased 
in the DIO + oxfen vs. DIO groups (86.23 ±7.01% vs. 53.79 ±1.67%). The overall effect 
of chronic oxfenicine treatment on cardiac mechanical function indicates that the drug 
has deleterious effects on control hearts and protective effects on DIO hearts.  
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Fig.3.1.7: Cardiac functional recovery, after 25 minutes of global ischemia and 20 
minutes of reperfusion, with and without oxfenicine treatment in the respective groups. 
All values are expressed as the mean ± SEM. Sample size (n) = 10. *P< 0.0074, #P< 
0.0226, $P< 0.0001.  
 
 
The functional recovery was increased in the control vs. control + oxfen (74.44 ± 10.80% 
vs. 32.75 ± 6.17%). There was a significantly improved functional recovery seen in the 
control rats vs. DIO groups (74.44 ± 10.80% vs. 40.90 ±6.21%). Recovery was higher in 
the DIO + oxfen vs. DIO groups (89.31 ± 1.18% vs. 40.90 ±6.21%). The overall effect of 
chronic oxfenicine treatment on cardiac mechanical function indicates that the drug has 
deleterious effects on control hearts and protective effects on DIO hearts.  
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Fig.3.1.8: Infarct size for the four experimental groups as determined using TTC staining, 
after 40 minutes regional ischemia and 2 hours reperfusion. The infarct size is expressed 
as a percentage (%) of the area at risk. Mean ± SEM are given. Sample size (n) = 10. *P< 
0.01, #P< 0.0047, $P< 0.001.  
 
 
The infarct size was significantly larger in the control + oxfen rats vs. control rats (59.37 
± 5.49 % of AAR vs. 32.05 ± 3.62 % of AAR). With treatment, there was also a 
significant decrease in the infarct size of DIO + oxfen (20.79 ± 3.19% of AAR) vs. DIO 
rats (61.70 ± 8.45% of AAR). The infarct size of the control hearts was significantly 
smaller vs. that of the DIO hearts (32.05 ± 3.62 % of AAR vs. 61.70 ± 8.45% of AAR). 
Chronic oxfenicine treatment appears to improve the myocardial tolerance to 
ischemia/reperfusion injury, in DIO group and decreases tolerance of the control hearts. 
There were inherent differences in the myocardial tolerance to ischemia/reperfusion 
injury in the control and DIO groups, as expressed by the infarct size.  
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3.2 Isolated mitochondria data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.2.1: Mitochondrial state 3 respiration recovery for the four experimental groups as 
determined by oxygraph mitochondrial assessment. The substrate used was glutamate. 
Mean ± SEM are given. Sample size (n) = 6. *P< 0.0253, #P<0.0060. 
 
 
There were no significant differences between the Control rats vs. DIO rats (69.17± 
3.22% vs. 62.99 ± 3.83%). The effect of the drug was seen as it decreased the percentage 
recovery of state 3 respiration of the control + oxfenicine group vs. control group (55.97 
± 3.87% vs. 69.17 ±3.22%). In contrast to this, there was a significant increase in the 
percentage recovery of state 3 respiration of the DIO + oxfenicine group vs. DIO group 
(72.93± 5.83% vs. 62.99± 3.83%). It appears that after chronic oxfenicine treatment, 
control rat mitochondrial state 3 respiration recoveries were much lower than that of the 
control rats without treatment and recoveries of the DIO rats + oxfenicine were much 
higher than that of the DIO rats without oxfenicine. 
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Fig.3.2.2: Myocardial oxygen consumption (QO2) (nmol O2/min/mg protein) for the four 
experimental groups as determined by oxygraph mitochondrial assessment. The substrate 
used was glutamate. Mean ± SEM are given. Sample size (n) = 6, *P<0.0001, #P<0.0013, 
$P<0.0002. 
 
 
Myocardial oxygen consumption was significantly lower in the Control vs. the Control + 
oxfenicine group (174.1± 13.08 nmol O2/min/mg protein vs. 323.5±15.81 nmol 
O2/min/mg protein). It was higher in the DIO group vs. Control group (263.0± 15.43 
nmol O2/min/mg protein vs. 174.1± 13.08 nmol O2/min/mg protein). The oxygen 
consumption was significantly decreased in the DIO + oxfenicine vs. DIO group (151.1± 
12.25 nmol O2/min/mg protein vs. 263.0± 15.43 nmol O2/min/mg protein). It appears that 
the diet did affect the oxygen consumption as shown by the increase in the oxygen 
consumption of the DIO group. Furthermore, the drug also affected the oxygen 
consumption in both the Control- and DIO groups. 
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Fig.3.2.3: ADP phosphorylation rate (nmol ADP/min/mg protein) for the four 
experimental groups as determined by oxygraph mitochondrial assessment. The substrate 
used was glutamate. Mean ± SEM are given. Sample size (n) = 6, P>0.05. 
 
 
There were no significant differences in any of the four groups. Control vs. DIO (491.7± 
41.87 nmol ADP/min/mg protein vs. 442.3± 26.89 nmol ADP/min/mg protein). Control 
vs. Control + oxfenicine (491.7± 41.87 nmol ADP/min/mg protein vs. 395.6±60.71 nmol 
ADP/min/mg protein) and DIO vs. DIO + oxfenicine (442.3± 26.89 nmol ADP/min/mg 
protein vs. 398.9±34.22 nmol ADP/min/mg protein).  
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Fig.3.2.4: Mitochondrial ADP: O ratio for the four experimental groups as determined by 
oxygraph mitochondrial assessment. The substrate used was glutamate. Mean ± SEM are 
given. Sample size (n) = 6. *P< 0.0107, #P< 0.00018, $P< 0.0048 
 
 
The ADP: O ratio was significantly higher in the control vs. the DIO group (2.00± 0.11 
vs. 1.32± 0.12). It was decreased in the control + oxfenicine vs. control group (1.65± 0.03 
vs. 2.00± 0.11). The ratio was significantly increased in the DIO + oxfenicine vs. DIO 
group (1.81± 0.01 vs. 1.31± 0.12). It appears that the diet had an effect on the ADP: O 
ratio as shown by the decrease in this ratio in the DIO group. Furthermore, the drug also 
affected the ADP: O ratios of the control + oxfenicine vs. the control group (1.65± 0.03 
vs. 2.00± 0.11) 
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Fig.3.2.5: Respiratory control index (RCI) for the four experimental groups as 
determined by oxygraph mitochondrial assessment. The substrate used was glutamate. 
Mean ± SEM are given. Sample size (n) = 6, P> 0.05. 
 
 
There were no significant differences in any of the groups. Respiratory control index 
(RCI) of Control vs. DIO (3.32± 0.28 vs. 3.92± 0.45), Control vs. Control + oxfenicine 
(3.32± 0.28 vs. 4.15± 0.75) and DIO vs. DIO + oxfenicine (3.92± 0.45vs. 4.11± 0.33). 
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Fig.3.2.6: Mitochondrial state 3 respiration recovery for the four experimental groups as 
determined by oxygraph mitochondrial assessment. The substrate used was palmitate. 
Mean ± SEM are given. Sample size (n) = 3, P>0.05. 
 
 
There were no significant differences in any of the four groups. Control vs. DIO (63.03± 
1.59% vs. 62.10± 6.57%). Control vs. Control + oxfenicine (63.03± 1.59% vs. 60.43± 
2.25%) and DIO vs. DIO + oxfenicine (62.10± 6.57% vs. 65.67±0.50%).  
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Fig.3.2.7: Myocardial oxygen consumption (QO2) (nmol O2/min/mg protein) for the four 
experimental groups as determined by oxygraph mitochondrial assessment. The substrate 
used was palmitate. Mean ± SEM are given. Sample size (n) = 3, *P<0.0036, #P<0.037, 
$P<0.028. 
 
 
Myocardial oxygen consumption was significantly lower in the Control vs. the Control + 
oxfenicine group (130.0± 21.70 nmol O2/min/mg protein vs. 361.0± 30.99 nmol 
O2/min/mg protein). It was higher in the DIO group vs. Control group (364.7± 73.11 
nmol O2/min/mg protein vs. 130.0± 21.70 nmol O2/min/mg protein). The consumption 
was significantly decreased in the DIO + oxfenicine vs. DIO group (116.0± 7.21 nmol 
O2/min/mg protein vs. 364.7± 73.11 nmol O2/min/mg protein). The diet did have an 
effect on the oxygen consumption as shown by the increase in the oxygen consumption of 
the DIO group. Furthermore, the drug also affected the oxygen consumption in both the 
Control- and DIO groups. 
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Fig.3.2.8: ADP phosphorylation rate (nmol ADP/min/mg protein) for the four 
experimental groups as determined by oxygraph mitochondrial assessment. The substrate 
used was palmitate. Mean ± SEM are given. Sample size (n) = 3, *P<0.0055 
 
 
There were no significant differences in the Control vs. DIO groups (842.10± 187.60 
nmol ADP/min/mg protein vs. 531.10± 73.06 nmol ADP/min/mg protein). Control vs. 
Control + oxfenicine (842.10± 187.60 nmol ADP/min/mg protein vs. 404.10± 103.30 
nmol ADP/min/mg protein) were statistically similar. The ADP phosphorylation rate was 
significantly lower in the DIO group vs. DIO + oxfenicine group (531.10± 73.06 nmol 
ADP/min/mg protein vs. 1121.10± 79.54 nmol ADP/min/mg protein).  
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Fig.3.2.9: Mitochondrial ADP: O ratio for the four experimental groups as determined by 
oxygraph mitochondrial assessment. The substrate used was palmitate. Mean ± SEM are 
given. Sample size (n) = 3, *P<0.0166, #P<0.0116, $P<0.0130 
 
 
The ADP: O ratio was significantly higher in the Control vs. DIO (2.93± 0.26 vs. 1.20± 
0.35). Control vs. Control + oxfenicine showed higher ADP: O ratios (2.93± 0.26 vs. 
1.23± 0.28) and lower ratios were seen in the DIO group vs. DIO + oxfenicine group 
(1.20± 0.35 vs. 3.1± 0.26). 
 
 
 
 
 
 
 
 
 
* 
# $ 
C
on
tr
ol
D
IO
0
1
2
3
4
Vehicle
Plus Oxfenicine
Groups
A
D
P
: 
O
 R
a
ti
o
 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.2.10: Respiratory control index (RCI) for the four experimental groups as 
determined by oxygraph mitochondrial assessment. The substrate used was palmitate. 
Mean ± SEM are given. Sample size (n) = 3, *P< 0.1014 
 
 
Respiratory control index was significantly lower in the Control vs. DIO groups (3.87± 
0.27 vs. 4.90± 0.40). There were no significant differences in any of the other groups. 
Control vs. Control + oxfenicine (3.87± 0.27 vs. 3.93± 0.23) and DIO vs. DIO + 
oxfenicine (4.90± 0.40 vs. 4.90± 0.26). 
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3.3 Western Blot Data 
 
The representative blot in each group shows three hearts per group. Beta tubulin was used 
to indicate equal loading. 
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Fig.3.3.1: Total CPT-1 expression with and without oxfenicine treatment. Expression of 
hearts freeze clamped after 30 minutes reperfusion. Mean ± SEM are given. Sample size 
(n) = 6, *P<0.0137 
 
There were no significant differences between the dietary groups. Control vs. DIO 
(28904± 1530 AU vs. 22792± 3383 AU). Control vs. Control + oxfenicine (28904± 1530 
AU vs. 23550± 3777 AU) were not significantly different. However the CPT 1 
expression was significantly decreased in the DIO + oxfenicine vs. the DIO group treated 
group (12159± 1119 AU vs. 22792± 3383 AU). 
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Fig.3.3.2: Total MCAD expression with and without oxfenicine treatment. Expression of 
hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are given. Sample 
size (n) = 6, P >0.05. 
 
 
There were no significant differences in total MCAD expression between any of the 
groups. Control vs. DIO (40842± 4212 AU vs. 35247± 3899 AU). Control vs. Control + 
oxfenicine (40842± 4212 AU vs. 34053± 8118 AU) and DIO vs. DIO + oxfenicine 
(35247± 3899 AU vs. 29453± 5209 AU). 
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Fig.3.3.3: Phosphorylated IRS-1 (Serine 641) with and without oxfenicine treatment. 
Expression of hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are 
given. Sample size (n) = 6, *P <0.03. 
 
 
Phosphorylated IRS-1 was significantly higher in the DIO group vs. Control group 
(33170± 2316 AU vs. 24463± 2654 AU). There were no significant differences between 
the following groups: Control vs. Control + oxfenicine (24463± 2654 AU vs. 25691± 
4346 AU) and DIO vs. DIO + oxfenicine (33170± 2316 AU vs. 30089± 5973 AU). 
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Fig.3.3.4: Total IRS-1 expression with and without oxfenicine treatment. Expression of 
hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are given. Sample 
size (n) = 6, *P <0.022, #P<0.0024 
 
Total IRS-1 expression was significantly increased in the control + oxfen group vs. 
control group (157813± 15284 AU vs. 113219± 6373 AU). The expression was not 
different between the control group vs. DIO group (113219± 6373 AU vs. 113601± 
18504 AU). Total IRS-1 expression was significantly decreased in the DIO + oxfen group 
vs. DIO group (76610± 5673 AU vs. 113601± 18504 AU). 
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Fig.3.3.5: Ratio of Phospho/total IRS-1 with and without oxfenicine treatment. Hearts 
were freeze clamped after 30 minutes of reperfusion. Mean ± SEM are given. Sample 
size (n) = 6, P>0.05 
 
 
There were no significant differences between any of the groups. Control vs. DIO (0.22± 
0.03 vs. 0.35± 0.08). Control vs. Control + oxfenicine (0.22± 0.03 vs. 0.18 ± 0.03) and 
DIO vs. DIO + oxfenicine (0.34± 0.08vs. 0.41 ± 0.20). 
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Fig.3.3.6: Total GLUT-4 expression with and without oxfenicine treatment. Expression 
of hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are given. Sample 
size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups. Control vs. DIO 
(24815± 3686 AU vs. 25597± 2450 AU). Control vs. Control + oxfenicine (24815± 3686 
AU vs. 29468± 3067 AU) and DIO vs. DIO + oxfenicine (25597± 2450 AU vs. 32618± 
5703 AU). 
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Fig.3.3.7: Levels of phosphorylated ERK- 44 and ERK- 42 with and without oxfenicine 
treatment. Expression of hearts freeze clamped after 30 minutes of reperfusion. Mean ± 
SEM are given. Sample size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups when pERK 44 was 
compared between groups and pERK 42 was compared between groups. For pERK 44: 
Control vs. DIO (53510± 6561 vs. 51025± 6391 AU). Control vs. Control + oxfenicine 
(53510± 6561 AU vs. 42101± 8314 AU) and DIO vs. DIO + oxfenicine (51025± 6391 
AU vs. 52388± 7994 AU). For pERK 42: Control vs. DIO (51293± 3044 AU vs. 61514± 
7705 AU). Control vs. Control + oxfenicine (51293± 3044 AU vs. 56194± 6205 AU) and 
DIO vs. DIO + oxfenicine (61514± 7705 AU vs. 60921± 4820 AU). 
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Fig.3.3.8: Levels of total ERK- 44 and ERK- 42 with and without oxfenicine treatment. 
Expression of hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are 
given. Sample size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups when tERK 44 was 
compared between groups and tERK 42 was compared between groups. For tERK 44: 
Control vs. DIO (108701± 4374 AU vs. 89377± 6248 AU). Control vs. Control + 
oxfenicine (108701± 4374 AU vs. 94984± 2652 AU) and DIO vs. DIO + oxfenicine 
(89377± 6248 AU vs. 106880± 3945 AU). For tERK 42: Control vs. DIO (41152± 1931 
AU vs. 35952± 1917 AU). Control vs. Control + oxfenicine (41152± 1931 AU vs. 
40392± 612.6 AU) and DIO vs. DIO + oxfenicine (35952± 1917 AU vs. 42679± 1075 
AU). 
44 kDa 
42 kDa 
   Control       C + Oxfen           DIO     DIO + Oxfen 
0
20000
40000
60000
80000
100000
120000
ERK42
ERK44
Control C + Ox D + OxDIO
A
rb
it
ra
ry
 d
e
n
s
it
o
m
e
tr
y
 u
n
it
 81 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.3.9: Ratio of Phosphorylated/total ERK (44/42) with and without oxfenicine 
treatment. Hearts were freeze clamped after 30 minutes of reperfusion. Mean ± SEM are 
given. Sample size (n) = 6, P>0.05 
 
 
There were no significant differences between any of the groups. For ERK 44: Control 
vs. DIO (0.49± 0.05 vs. 0.58 ± 0.08). Control vs. Control + oxfenicine (0.49± 0.05 vs. 
0.45± 0.09) and DIO vs. DIO + oxfenicine (0.58 ± 0.08 vs. 0.50± 0.08). For ERK 42: 
Control vs. DIO (1.39± 0.12 vs. 1.733± 0.22). Control vs. Control + oxfenicine (1.39± 
0.12 vs. 1.37± 0.13) and DIO vs. DIO + oxfenicine (1.73± 0.22 vs. 1.355 ± 0.14). 
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Fig.3.3.10: Phosphorylated PKB expression with and without oxfenicine treatment. 
Expression of hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are 
given. Sample size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups. Control vs. DIO 
(25909± 3185 AU vs. 32716± 4600 AU). Control vs. Control + oxfenicine (25909± 3185 
AU vs. 29953± 4136 AU) and DIO vs. DIO + oxfenicine (32716± 4600 AU vs. 32180± 
4646 AU). 
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Fig.3.3.11: Total PKB expression with and without oxfenicine treatment. Expression of 
hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are given. Sample 
size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups. Control vs. DIO 
(26518± 4348 AU vs. 26821± 6446 AU). Control vs. Control + oxfenicine (26518± 4348 
AU vs. 25910 ± 4769 AU) and DIO vs. DIO + oxfenicine (26821± 6446 AU vs. 27527± 
4605 AU). 
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Fig.3.3.12: Ratio of Phosphorylated/total PKB with and without oxfenicine treatment. 
Expression of hearts freeze clamped after 30 minutes of reperfusion. Mean ± SEM are 
given. Sample size (n) = 6, P >0.05. 
 
 
There were no significant differences between any of the groups. Control vs. DIO (1.09± 
0.17 vs. 1.04± 0.05). Control vs. Control + oxfenicine (1.09± 0.17 vs. 0.96± 0.09) and 
DIO vs. DIO + oxfenicine (1.04± 0.05 vs. 1.35 ±0.27). 
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CHAPTER 4: 
DISCUSSION OF RESULTS 
 
Effects of chronic oxfenicine on bodyweights 
 
In our study it was important to investigate the efficacy of the switch from fatty acid 
oxidation to glucose oxidation, in a high calorie induced model of obesity and metabolic 
syndrome. This is an established model and has been in use in our department for a 
number of years (Du Toit et al. 2008; Essop et al. 2009). The body weights were 
significantly higher in both the DIO groups when compared to the control groups (Fig. 
3.1.1). The drug, oxfenicine is an inhibitor of fatty acid oxidation and therefore it is 
highly unlikely to influence body weights. 
 
The increased retro-peritoneal fat weights also gave an indication that the DIO group had 
indeed gained weight over the 16 week period (Fig. 3.1.2). The drug had no effect on 
these fat depots. There is no evidence in literature of any study which indicated that 
oxfenicine had an effect on bodyweight or intra peritoneal fat weight.  
 
 
Impact of chronic oxfenicine treatment on: 
 
Myocardial function before ischemia 
 
Our basal mechanical function data show no significant differences in any of the groups 
(Fig. 3.1.3). It has been shown that the obese rat heart has reduced cardiac mechanical 
function compared to controls. The reduced function is observed in both basal conditions 
as well as after an ischemic event (Du Toit et al. 2008; Essop et al. 2009). Reduced basal 
function in the DIO groups compared to the control groups was not obtained in our study. 
Essop et al. (2009) represented data that showed reduced basal function in the DIO rats 
when compared to the controls. These authors perfused the hearts on a working heart 
perfusion apparatus while we used a Langendorff perfusion system. The heart is not in an 
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active contractile state on the Langendorff system. This could explain why we did not see 
any functional differences between the control and obese hearts. The work heart 
perfusion system is much more sensitive to functional differences between control and 
obese hearts, than the Langendorff perfusion system. The work done by Essop et al. 
(2009) was in the same animal model as in our study, but hearts were perfused with a 
buffer containing glucose and no palmitate or insulin. This could be another reason for 
the fact that they observed worsened function in the DIO rats while we could not. This is 
in line with findings by Taegtmeyer (2000) who state that the normal heart function is 
better when both fatty acids and glucose is present in the perfusate. In another study done 
by Du Toit et al. (2008) the addition of insulin (30µIU/ml or 50µIU/ml) before ischemia 
appears to improve the mechanical function of the DIO rat hearts and may have played a 
role. In addition, it has been shown that oxfenicine does not affect heart rate, coronary 
flow or arterial blood pressure (Stephens & Higgins, 1985). 
 
 
Myocardial function after ischemia 
 
After regional ischemia (40 minutes), global ischemia (25 minutes) and reperfusion (10- 
and 20 minutes), we found that the myocardial function of the DIO groups was 
significantly reduced compared to controls (Fig. 3.1.4 to Fig. 3.1.7). The reason for the 
different ischemic times used in the two protocols is one of a practical nature i.e. during 
global ischemia the whole heart is made ischemic as opposed to regional ischemia, where 
just a region of the heart is made ischemic. Therefore the time of ischemia cannot be the 
same for both types of ischemia, as global ischemia for 40 minutes (as with regional 
ischemia) would be too severe on the heart and leads to total mechanical failure during 
reperfusion. With global ischemia of 25 minutes, the heart can evoke pressure and 
therefore mechanical function can still be recorded. Furthermore, 40 minutes of regional 
ischemia yield an average infarct size of ~40% and thus creating an opportunity to either 
increase or decrease the infarct size. Du Toit et al. (2008) show data of decreased 
contractile function in DIO rats, which was possibly due to what they refer to as a 
hypertrophic response. This hypertrophic response is characterized by increased wall 
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thickness followed by dilation and contractile dysfunction. We found similar results after 
subjecting the hearts to ischemia/reperfusion which would suggest they were more prone 
to ischemia/reperfusion injury. 
 
Oxfenicine is known to improve cardiac contractile function in control animals before 
and after ischemic insults (Burges et al. 1981; Molaparast-Sales, Liedtke & Nellis, 1987; 
Chavez et al. 2003; Chandler et al. 2003; Broderick & Glick, 2004). This effect is 
attributed to the stimulation of glucose oxidation and decrease in lactate production 
(Stephens & Higgins, 1985; Higgins et al. 1981). However, to our knowledge, there is no 
current data on the effects of chronic oxfenicine treatment in a model of diet induced 
obesity. Our results show that the drug significantly improved the cardiac mechanical 
function of the DIO group treated with oxfenicine compared to the DIO group without 
the drug. The improved function in the DIO rats has not been shown before and could be 
due to the stimulation of glucose/pyruvate metabolism (Stephens & Higgins, 1985; 
Higgins, Morville & Burges, 1981; Burges, Gardiner & Higgins, 1981; Molaparast-Sales, 
Liedtke & Nellis, 1987). Similar results have been found in studies in which animals 
were treated with oxfenicine and where improvement in cardiac mechanical function was 
observed. These findings of the effects of oxfenicine on cardiac function were 
investigated in different experimental models. In a domestic pig model, oxfenicine 
improved contractile function and cardiac efficiency during demand ischemia (Chavez et 
al. 2003; Chandler et al. 2003). Broderick and Glick (2004) found that acute oxfenicine 
treatment (2mM oxfenicine in perfusate) in age matched male and female Sprague-
Dawley rats improved the recovery of systolic pressure, cardiac output and ventricular 
contraction. 
 
The control + oxfenicine groups had reduced function when compared to the untreated 
animals. The worsened function could be linked to oxfenicine induced cardiotoxicity. 
Oxfenicine has been shown to cause (1) cardiac-, liver- and kidney hypertrophy, (2) 
uncoupling of oxidative phosphorylation, (3) phospholipid-, triglyceride- and fatty acid 
accumulation as well as (4) inhibition of myocyte membrane components, in control rats 
(Bachmann & Weber, 1988). In the above mentioned study the administered dose of 
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oxfenicine was 150mg/kg/day for a period of 8 weeks in control lean animals. In 1988, it 
was shown that oxfenicine caused lipid accumulation with an intraperitoneal injection of 
60mg/kg (Jodalen et al. 1988). Oxfenicine treatment has also been associated with 
cardiac hypertrophy at a dosage of 900mg/kg/day (for up to 2 years, only after three 
months) (Higgins, Morville & Burges, 1981; Higgins, Morville & Burges, 1980; Greaves 
et al. 1984). All of the above mentioned factors could explain the marked decrease in 
cardiac function in control rats. However, Okere et al. (2007) recently found that at a 
dosage of 200mg/kg/day, oxfenicine showed none of these negative effects on the rat 
myocardium. In the same study oxfenicine caused increased cardiac triglyceride levels in 
control rats fed a high saturated fatty acid diet. 
 
There seems to be a few factors that play a role in the vast range of effects reported for 
oxfenicine. These include dosage, duration of treatment, mode of administration 
(injection or ingestion), animal model (control, obese, heart failure/hypertrophy), and the 
type of diet as well as additional effects of other interventions such as ischemia and/or 
reperfusion. The influence of these factors may explain why reason oxfenicine treatment 
yields different effects in the published studies. 
 
Studies of Bachmann and Weber in (1984), Stephens and Higgins (1985), Higgins, 
Morville & Burges, 1981 and Greaves et al. (1984) only briefly discuss the effects of 
oxfenicine on the liver. It should be kept in mind that in our study, this drug was 
administered over a period of 8 weeks and was supplemented in the drinking water. 
Results from the study of Bachmann and Weber in (1984), Stephens and Higgins (1985) 
and Finck et al. (2005) are an indication that oxfenicine possibly has uncharacterised 
effects on the liver and possibly other organs like the kidney and skeletal muscle (Finck 
et al. 2005; Higgins, Morville & Burges, 1981). It is therefore possible that the 
inconsistency in oxfenicine effects seen in our data and the literature is not only due to 
oxfenicine‘s influence on the heart but also on other organs (Bachmann & Weber, 1984; 
Jodalen et al. 1988; Higgins, Morville & Burges, 1981; Greaves et al. 1984; Okere et al. 
2007; Chavez et al. 2003; Chandler et al. 2003; Stephens & Higgins, 1985; Higgins et al. 
1981; Burges, Gardiner & Higgins, 1981; Molaparast-Sales, Liedtke & Nellis, 1987).  
 89 
Infarct size 
 
When the susceptibility to ischemia/reperfusion was determined in our study, the infarct 
size was significantly larger in the DIO group compared to the control group (Fig. 3.1.8). 
This has been previously described by other investigators (Essop et al. 2009; Boudina & 
Abel, 2005). The mechanism for this phenomenon could be related to the mitochondrial 
permeability transition pore (mPTP) which is thought to play a role in myocardial cell 
death during ischemia/reperfusion (Hausenloy & Yellon, 2003). Multiple factors may 
play a role and these include altered lipoprotein levels, ectopic cardiac triglyceride lipid 
deposition, activation of inflammatory pathways, metabolic derangements, perturbed 
mitochondrial respiratory capacity and mitochondrial dysfunction (for details see reviews 
by Boudina & Abel 2005; Bugger & Abel, 2008; Morin et al. 2001). We could not find 
differences in the basal cardiac mechanical function of the DIO group when compared to 
that of the control group. The differences in the DIO group compared to the control group 
were only evident after ischemia/reperfusion. This indicates that obesity predisposes the 
heart to ischemia/reperfusion injury but does not necessarily compromise cardiac 
function under normoxic conditions. 
 
Control rats treated with oxfenicine had significantly larger infarcts in comparison to 
untreated controls, which could also be related to the oxfenicine induced cardiotoxicity 
reported by Bachmann and Weber (1988). The DIO rats treated with oxfenicine displayed 
smaller infarct size than the DIO rats without treatment. Infarct size was even smaller 
than those of the controls. This correlates with data from other groups who showed that 
oxfenicine treatment protects the heart against necrotic damage during ischemia and it 
reduced infarct size (Higgins, Morville & Burges, 1980; Korb et al. 1984; Stephens et al. 
1985; Vik-Mo et al. 1986; Kong et al. 2002). Data on trimetazidine, another inhibitor of 
fatty acid oxidation, suggests that this drug might decrease mitochondrial uncoupling and 
increase the production of membrane protective glycolytic ATP (Essop & Opie, 2004). 
This could also apply to oxfenicine. Another proposal is that the experimental stimulation 
of glucose oxidation, prior to and during ischemia, might cause a rise in intracellular pH 
(basic) and decrease Na
+
/Ca
2+
 exchange. This might lead to reduced intra-cellular 
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calcium overload and eradication of cell death/necrosis (Haigney et al. 1992; Liu et al. 
1996a; Liu et al. 1996b; Liu et al. 2002). Furthermore it has been shown that oxfenicine 
efficiently prevents cell death (Kong et al. 2002). These are all possible mechanisms for 
the reduction in the infarct size in the DIO rats treated with oxfenicine compared to the 
DIO rats without oxfenicine treatment. 
 
For MS there are existing mechanisms for reduced contractile function and susceptibility 
to ischemia/reperfusion. These mechanisms include: (1) increased rates of fatty acid 
oxidation and (2) uncoupling of mitochondrial respiration (Bugger & Abel, 2008). Thus, 
in the case of our study, it was important to investigate these mechanisms (whether the 
diet had an effect) as well as to investigate the effects of the drug. Therefore we set out to 
assess mitochondrial respiration and the different proteins within the energy metabolism 
pathways and the RISK pathway. 
 
 
Mitochondrial function 
 
State 3 respiration recoveries: glutamate or palmitate as substrate 
 
When glutamate was used as substrate there was no difference in the state 3 respiration 
recovery (after 25 minutes anoxia followed by 6 minutes re-oxygenation) in the DIO 
group when compared with the control group (Fig. 3.2.1 and Fig. 3.2.6). This is in line 
with the findings of Essop et al. (2009) who showed that the DIO animals have impaired 
contractile function and impaired mitochondrial respiratory capacity. We could not find 
any uncoupling of mitochondrial respiration in the DIO groups, in contradiction to the 
concept that type 2 diabetes mellitus (T2DM) and the metabolic syndrome (specifically 
obesity) lead to mitochondrial dysfunction/uncoupling of mitochondrial respiration (See 
review by Bugger & Abel 2008). 
 
This further supports our existing knowledge that our animal model is not one of diabetic 
but rather a model of pre-diabetes and insulin resistance (and/or transient insulin 
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resistance) (Du Toit et al. 2008). This would still qualify the model as one of the 
metabolic syndrome. The state 3 respiration recoveries were significantly reduced in the 
control groups + oxfenicine when compared to the control groups without treatment. This 
is in agreement with the results in a study by Bachmann and Weber (1988). Oxfenicine 
treatment improved the state 3 respiration percentage recoveries of the DIO rats 
compared to the DIO rats without treatment. Although there were no differences between 
the recoveries of the DIO group vs. the control group, it should be noted that the recovery 
of the DIO + oxfenicine rats was increased to control levels. 
 
We assessed mitochondrial respiration using palmitoyl L-carnitine (palmitate) as 
substrate, but with an n of 3. (Numbers were restricted due to funding and animal 
availability). State 3 respiration percentage recovery data showed no differences in any of 
the groups, when palmitate was used as substrate. The fact that we could not detect 
differences could be due to the small sample size or that there simply were no 
differences. 
 
 
Myocardial oxygen consumption (QO2) with glutamate or palmitate as substrate 
 
Oxygen consumption was significantly higher in the DIO groups in comparison with the 
controls, with glutamate as substrate (Fig. 3.2.2 and Fig. 3.2.7). This could be due to 
oxygen wastage with increased fatty acid oxidation, since more oxygen is required to 
produce equivalent amounts of ATP during fatty acid oxidation (Essop & Opie, 2004). 
 
Taking this into consideration, the question might arise as to why there would be 
increased oxygen consumption in the DIO rats when our results show no mitochondrial 
uncoupling. This could be due to the fact that our model is not fully diabetic but rather 
pre-diabetic and/or transiently insulin resistant and thus complete uncoupling is not yet 
evident, mitochondria might still be in transition into uncoupling. Furthermore, even 
though the oxygen consumption is significantly increased, it might not be severe enough 
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to impair mitochondrial respiratory capacity/respiratory recovery ability or cause 
mitochondrial uncoupling. 
 
Oxfenicine increased the oxygen consumption in the control rats when compared to 
controls without oxfenicine. This negative effect might also relate to oxfenicine induced 
cardiotoxicity (Bachmann & Weber, 1988). Oxfenicine causes an increase in 
mitochondrial oxygen consumption in the control rats. This indicates oxygen wastage and 
may be a mechanism by which the negative effects of the drug are caused. Therefore, in 
retrospect, it appears that the same drug that decreases oxygen consumption in the DIO 
rats causes its increase in the control rats. The possible factor that signals the absence of 
oxygen wastage in the one group but not in the other group again raises the issue of 
elevated levels of fatty acids, which are known to cause oxygen wastage (Essop & Opie, 
2004). Thus the oxfenicine induced lipid accumulation could exacerbate oxygen wastage 
in the control rats treated with oxfenicine. 
 
DIO rats treated with oxfenicine displayed decreased oxygen consumption. The exact 
mechanism for this improvement remains unclear. This finding correlates with the 
improved state 3 respiration recoveries, infarct size and function during reperfusion. 
 
Myocardial oxygen consumption when palmitate was used as substrate followed the same 
pattern as when glutamate was used as a substrate. Therefore the same rationale regarding 
possible mechanisms are applicable as described earlier. With regards to the oxygen 
consumption during the experiments with palmitate as fuel substrate, it should be noted 
that the pattern of changes between groups is similar but more pronounced. These 
changes are 1) an increase in oxygen consumption of controls + oxfenicine compared to 
the controls, 2) higher oxygen consumption in DIO rats compared to controls and 3) 
decreased oxygen consumption in DIO rats + oxfenicine when compared to DIO rats 
without oxfenicine. The more pronounced differences seen between the groups, when 
palmitate is used, is in line with the notion that palmitate is more representative and a 
better reflection of mitochondrial uncoupling since fatty acids are the main fuel for the 
adult mammalian heart in vivo or ex vivo (Essop et al. 2009). 
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ADP phosphorylation rates with glutamate or palmitate as substrate 
 
Our data show no differences in the ADP phosphorylation rates in any of the groups 
when glutamate was used as substrate (Fig. 3.2.3 and Fig. 3.2.8). Similar results were 
obtained in the study done by Essop et al. (2009). From their study, the conclusion can be 
made that differences in ADP phosphorylation rates between control hearts and DIO 
hearts are dependent on the type of substrate used. When glutamate was used as substrate, 
there were no differences in the ADP phosphorylation rates of the DIO rats compared to 
the control rats. When palmitate was used, they observed higher ADP phosphorylation 
rates in the control rats when compared to the DIO rats. 
 
However in our study, the ADP phosphorylation rates when palmitate was used as 
substrate showed no differences between the control rats compared to the DIO rats. As 
discussed previously this could possibly be because this obese model is not fully diabetic 
but rather pre-diabetic and transiently insulin resistance. No differences were observed 
between the ADP phosphorylation rates of control rats and control rats + oxfenicine. 
Another explanation could also be the small sample size in our study (n=3). The ADP 
phosphorylation rates were significantly increased in the DIO + oxfenicine group when 
compared to the DIO group without oxfenicine. When glutamate was used as substrate 
we observed no differences in any of the groups. This could suggest that for each type of 
substrate the ADP phosphorylation rates are unique and differ. 
 
 
ADP: O ratios with glutamate or palmitate as substrate 
 
When glutamate was used as substrate we found that the ADP: O ratios were lower in the 
DIO rats in comparison to the control rats (Fig. 3.2.4 and Fig. 3.2.9). This is just a 
representation of our data that showed an increase in oxygen consumption and no change 
in the ADP phosphorylation rates in these groups. This suggests that the level of obesity 
or the effect of the high caloric diet might be sufficient to cause oxygen wastage but not 
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sufficient to influence ADP phosphorylation rates (and thus not sufficient to diminish 
ATP production). 
 
The ADP: O ratios were increased in the DIO rats treated with oxfenicine compared to 
the DIO rats without treatment. It should be noted that even though the statistical 
software expressed the ADP: O ratios of the oxfenicine treated DIO rats as significantly 
increased; the value of this ratio is raised to that of the control rats. This makes the ADP: 
O ratios similar to those of the control rats. The ADP: O ratios when palmitate was used 
as substrate, followed the same pattern as when glutamate was used as a substrate. 
Therefore the same rationale is applicable. With the ADP: O ratios during the use of 
palmitate as fuel substrate, it should be noted that the pattern of changes between groups 
are similar but more pronounced. These changes are: i) increase in ADP: O ratios of 
controls + oxfenicine compared to controls without oxfenicine, ii) higher ADP: O ratios 
in DIO rats compared to controls without oxfenicine and iii) decreased ADP: O ratios in 
DIO rats + oxfenicine when compared to DIO rats without oxfenicine. The more 
pronounced differences seen between groups, when palmitate is used, is in line the 
concept that palmitate is more representative of mitochondrial uncoupling/energy 
substrate oxidation as fatty acids are the main fuel for the adult mammalian heart both in 
vivo and ex vivo (Essop et al. 2009). 
 
 
Respiratory control indexes with glutamate or palmitate as substrate 
 
There were no differences in the RCI values between any of the groups when glutamate 
was used as a substrate (Fig. 3.2.5). However when palmitate was used as a substrate, the 
RCI was higher in the DIO group when compared to the control group (Fig. 3.2.10). The 
RCI gives an indication of the tightness of coupling of ATP production to energy 
substrate oxidation (Lindenmeyer, Sordahl & Schwartz, 1968; Lanza & Nair, 2009). 
These data suggest that there was no mitochondrial uncoupling in any of the groups. The 
same results were obtained when palmitate was used as substrate.  
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Western blot data 
 
Obesity is known to be responsible for a whole range of molecular and metabolic 
pertubations, which ultimately influence cardiac function and susceptibility to 
ischemia/reperfusion injury (Dandona et al. 2005; Poirier et al. 2006). In light of this we 
also explored for possible changes in the beta oxidation pathway enzyme/protein 
expression and the involvement of the RISK pathway (namely ERK (44/42) and 
PBK/Akt) in the effects of oxfenicine in our study. All the Western blots were done on 
hearts that were subjected to 25 minutes of global ischemia and 30 minutes of 
reperfusion. Our western blot data highlighted some differences in protein expression and 
activation between study groups. 
 
 
Total CPT-1 expression 
 
The diet did not have an effect on the total CPT-1 expression (Fig. 3.3.1). Oxfenicine 
however decreased the expression in the DIO rat hearts when compared to the DIO rats 
without treatment (Fig. 3.3.1). The fact that the CPT-1 protein expression was decreased 
in the DIO rats treated with oxfenicine, may partly explain the dramatic positive effects 
seen in these DIO rats after treatment. The general understanding is that when a receptor 
is inhibited, the cell could be expected to respond by overriding the inhibitor‘s effect and 
increase receptor expression. 
 
This was not the case in our study, regarding the effect of oxfenicine on the CPT-1 
expression in the DIO rats. In an attempt to try and explain this finding, we reverted back 
to the basic pharmacology of the drug. We could not find information regarding the 
specific way in which oxfenicine inhibits CPT-1 in the heart. However, the consensus is 
that oxfenicine inhibits CPT-1 in a pH dependent manner, analogous with the mechanism 
of malonyl-CoA. Oxfenicine is also structurally similar to malonyl-CoA and could 
therefore inhibit CPT-1 in a similar manner (Stephens & Higgins, 1985). Lopez-Vinas et 
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al. (2007) proposed an in silico model of CPT-1 binding sites for malonyl-CoA (or 
oxfenicine). 
 
According to Lopez-Vinas et al. (2007), CPT-1 has two binding sites for inhibitors 
(malonyl-CoA and therefore also oxfenicine): one binding site of a high- and one- of a 
low affinity. These binding sites are said to be at the N- and C terminals of the receptor 
and the site Met
593 
amongst others, plays a major role in the inhibition of CPT-1. Under 
normal circumstances the cell would sense the availability of substrates (like lipids and 
carbohydrates) by means of AMPK such as after a low fat/high carbohydrate meal. The 
low availability of fatty acids activates malonyl-CoA which inhibits CPT-1, so that fatty 
acids are not broken down any further, but rather carbohydrates (Dyck et al. 2004). When 
fatty acid levels return to normal, the sensor (AMPK) signals the cell that fatty acid levels 
are normal. The inhibition by malonyl-CoA is aboished by an enzyme called malonyl-
CoA-decarboxylase (MCD), which decarboxylates and inactivates malonyl-CoA and thus 
the cell can increase CPT-1 protein expression. If the fatty acid levels increase or are 
continuously elevated, the cell would inactivate malonyl-CoA related CPT-1 inhibition 
and further increase CPT-1 protein expression, to correct for the extremely high levels of 
fatty acids. Therefore, with regards to fuel metabolism, the cell does not increase the 
protein expression as a means of counteracting the malonyl-CoA inhibition, but rather as 
an attempt to deal with the high levels of fatty acids. The increase in protein expression to 
counteract the inhibition of an inhibitor might only be of relevance in other forms of 
inhibition, with the absence of a sensor like AMPK. 
 
However the situation may change slightly when pharmacological inhibition (oxfenicine) 
of CPT-1 is induced. Now both oxfenicine and malonyl-CoA is present. These two agents 
will most probably compete for binding sites on CPT-1. Despite this, oxfenicine will 
inhibit CPT-1. When oxfenicine inhibits CPT-1, both the sensor (AMPK) malonyl-CoA 
is still active. 
 
It should be remembered that the DIO rats were already obese at 8 weeks while the 
controls were not, due to diet differences. Concerning the diets, the level of obesity in the 
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DIO rats causes elevation of FFA levels, which have been shown to increase uncoupling 
protein (UCP) expression (Bugger & Abel, 2008). At 8 weeks, control rats were not 
obese and thus the cell/heart had no stimulus to increase UCP expression. Concerning 
oxfenicine; the drug has been shown to, under some circumstances, cause cardiac tissue 
lipid accumulation. During the last 8 weeks, the DIO rat hearts were already exposed to 
elevated fatty acids from adipose tissue as well as elevated fatty acids caused by 
oxfenicine treatment. As elevated levels of fatty acids are known to increase UCP 
expression, this would further increase UCP expression. This creates the condition where 
both the diet and the drug ultimately lead to increased UCP expression. In the control 
animals, this was not the case, since their UCP expression levels would be normal, after 8 
weeks of their control diet. 
 
It is only after another 8 weeks of oxfenicine treatment, that lipid accumulation, caused 
by oxfenicine would increase UCP expression in the control animals. However, this is not 
as severe as that of the DIO rats, but rather intermediate in severity. Thus the DIO rat 
hearts would have dramatically higher UCP levels than the intermediately increased UCP 
levels in the controls. UCP‘s are known to be able to export fatty acids out of the 
mitochondria and decrease lipotoxicity (Opie & Knuuti, 2009), in fact, UCP‘s are 
believed to exist as an inherent cardiac adaptive or protective mechanism (Bugger & 
Abel, 2008). Therefore in the DIO rats the severely increased UCP‘s could possibly 
decrease the fatty acid levels. This would be sensed by the sensor (AMPK) and the cell 
would be signalled to decrease fatty acid breakdown and lead to decreased CPT-1 
expression. 
 
This decrease is even further exacerbated by the already present inhibition of CPT-1 and 
signals to the cell to further decrease CPT-1 expression. This could explain the decrease 
in CPT-1 protein expression in our DIO rats treated with oxfenicine. This decrease in 
CPT-1 expression would not occur in the control animals, since the intermediate level of 
UCP expression, caused by the drug, might not be enough to cause a decrease in CPT-1 
expression. Therefore no decrease in CPT-1 expression is detected. 
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Total MCAD expression 
 
There were no differences in the MCAD levels between any of the groups (Fig. 3.3.2). 
Neither the diet nor the drug had an affect on MCAD expression. This corroborates data 
from a study done by Okere et al. (2007) who also found that oxfenicine had no effect on 
MCAD expression. It is known that the metabolic changes which occur during the state 
of ischemia and insulin resistance are similar to those that occur during hypertrophy/heart 
failure (Opie & Knuuti, 2009). In another study in a rodent model of progressive 
hypertrophy, in vivo expression of MCAD was maintained at control levels (Lionetti et 
al. 2005). The reason for this unchanged MCAD expression after oxfenicine treatment 
remains unclear. If it is agreed that oxfenicine does inhibit CPT-1 activity, then MCAD 
activity should also be inhibited. MCAD protein expression levels should thus remain 
unchanged, but MCAD activity should be decreased. Therefore MCAD activity should be 
assessed in future studies rather than mere total expression. Okere et al. (2007) found that 
oxfenicine increased MCAD activity in control animals fed a diet of high saturated fatty 
acids.  
 
 
Phosphorylated and total IRS-1 expression 
 
The phosphorylation of IRS-1 (Ser 641) was significantly increased in the DIO group 
when compared to the control group (Fig. 3.3.3). There were no differences in IRS-1 
phosphorylation between the other groups. Total IRS-1 expression was significantly 
increased in the controls + oxfenicine when compared to the control without oxfenicine 
and decreased in the DIO + oxfenicine group compared to the DIO group (Fig. 3.3.4). 
There were no differences between the control group and DIO group. Guo and Tabrizchi 
(2006) proposed that a high circulation/uptake of free fatty acids (as during insulin 
resistance/pre-diabetes) is associated with incomplete beta oxidation and accumulation of 
fatty acid oxidation intermediates such as ceramide, acyl-CoA, and diacyl-glycerol. As a 
result, the expression and activity of protein kinase C-θ (PKC-θ) increase which changes 
the phosphorylation state of the insulin receptor substrate (IRS). Serine (641) binding site 
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phosphorylation is increased in insulin resistance/pre-diabetes. This reduces the ability of 
the IRS to stimulate PI3-kinase (Phosphatidyl-Inositol-3-phosphate-kinase). The reduced 
PI3-kinase activity, ultimately suppresses the glucose uptake by preventing Glucose 
Transporter-4 (GLUT-4) translocation to the cell membrane (Guo & Tabrizchi, 2006; 
McCarthy et al. 2005). 
 
The fact that we saw differences in the IRS-1 phosphorylation is in line with the concept 
proposed by Guo and Tabrizchi (2006). The drug increased the total IRS-1 expression in 
the control + oxfenicine group compared to the controls without oxfenicine. This could 
explain the negative effects of the drug in the control animals. Oxfenicine possibly 
induces insulin resistance in the control animal. Thus a situation is created that is similar 
to that present in the insulin resistant/pre-diabetic state (as described by Guo & Tabrizchi, 
2006). Another possible explanation for the increase in total expression in the control + 
oxfenicine group could be that oxfenicine inhibits beta oxidation and thus increases the 
accumulation of toxic beta oxidation metabolites. Thus the drug may further increase 
elevated fatty acid circulation/uptake which causes the serine (641) phosphorylation of 
IRS-1. The drug decreased the total expression of IRS-1 in the DIO group + oxfenicine. 
When observed individually, it might appear that there was phosphorylation of IRS-1 
(Ser 641) in the DIO groups. However, when the phosphorylated/total IRS-1 ratio was 
determined we could see no differences. Therefore oxfenicine did not influence the 
activation of IRS-1 even though it influenced the total expression. 
 
 
Total Glut 4 expression 
 
Our data showed no differences in the expression of total GLUT- 4 in any of the groups 
(Fig. 3.3.6). This could be due to the fact that a more direct measure of glucose uptake 
and activation of GLUT- 4 would be the assessment of GLUT- 4 translocation. Thus if 
oxfenicine did increase glucose uptake, mere GLUT- 4 protein expression would not 
reflect this change or the possible effect of the drug. This is in line with our current 
understanding of GLUT- 4 and glucose uptake. 
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Total and phosphorylated ERK (42/44) and PKB/Akt expression 
 
These kinases form part of the RISK pathway, a prosurvival signaling pathway which 
protects the myocardium against reperfusion-induced injury (Hausenloy & Yellon, 2004). 
We could not find any significant differences in the phosphorylated nor total ERK-44 and 
ERK 42 levels (Fig. 3.3.7 and Fig. 3.3.8) or the phosphorylated and total PKB/Akt. The 
ratio for phosphorylated/total ERK-44 and ERK-42 did not differ between groups, neither 
did the ratio for phosphorylated/total PKB/Akt. This ratio gives an indication of how 
much of the expressed protein is in actual fact phosphorylated. The fact that no 
differences were observed at 30 minutes does not necessarily mean there were no 
differences early in reperfusion. These kinases usually peak at about 15 minutes of 
reperfusion and then return towards basal levels (Hausenloy & Yellon, 2004, Hausenloy 
& Yellon, 2007). The conclusion is that the RISK pathway was not activated in any of the 
groups at the time point we investigated (i.e. 30 minutes reperfusion). 
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CHAPTER 5 
 
CONCLUSION 
 
From this study we can conclude that: 
 
1. Chronic oxfenicine treatment protects the obese heart during 
ischemia/reperfusion. 
2. Oxfenicine induced cardioprotection in obese animals appear to be due to the 
improvement of mitochondrial respiratory parameters (QO2, ADP: O ratios and 
ADP phosphorylation rates) without activation of the RISK pathway. 
3.  Chronic oxfenicine treatment has adverse effects on the hearts of control lean 
animals. 
4. Oxfenicine induced adverse effects in control animals may be due to worsening of 
mitochondrial respiratory parameters (QO2, ADP: O ratios and ADP 
phosphorylation rates) but does not involve the RISK pathway. 
5. There were no differences in the expression/activation of ERK, IRS-1 and 
PKB/Akt. MCAD and GLUT-4 expression remained unchanged whilst CPT-1 
expression was decreased in the DIO + oxfenicine group compared to the DIO 
group. 
 
Oxfenicine causes an increase in mitochondrial oxygen consumption in the control rats 
when compared to the normal controls. This indicates oxygen wastage and thus a possible 
mechanism by which oxfenicine causes its negative effects. In addition to this it might 
also be that the negative effects seen in the control rats + oxfenicine and the positive 
effects seen in the DIO rats + oxfenicine is not merely related to only CPT-1 inhibition 
but also an additional influence such as oxfenicine causing organ (liver, kidney) 
hypertrophy. The pronounced negative effects of oxfenicine or its pronounced positive 
effects might possibly be due to a systemic influence, additional to its local effects on the 
heart (Bachmann & Weber, 1988).  
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Based on the results of this study, it appears that chronic oxfenicine treatment may be an 
effective intervention if administered to metabolic syndrome animals. The treatment 
appears to protect the obese heart against ischemic injury and could therefore be used as a 
possible prophylactic treatment. At this stage, the toxicity of this drug remains unclear as 
many studies have reported a wide variety of consequences in various animal models post 
oxfenicine treatment, whether short term or long term. Extensive research is however still 
required before oxfenicine could be applied in clinical studies. 
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CHAPTER 6 
 
LIMITATIONS OF THE STUDY 
 
During this study we did not measure the direct effects of oxfenicine on myocardial 
glucose and beta oxidation. This could have been done by perfusions with radio-labelled 
glucose and palmitate. As this drug has never been tested (according to our knowledge) 
in a model such as ours, it may very well be that oxfenicine had an uncharacterised effect 
on myocardial fuel metabolism. This was however beyond the scope of this study. 
 
We could have assessed mitochondrial respiration with palmitate, but with a bigger 
sample size. This would have given us a better indication of respiration, as fatty acids are 
the major fuel of the adult mammalian heart. Again limited availability of animals 
dictated that group numbers were sometimes sub optimal. 
 
We could have done experiments on the working heart perfusion system, which may have 
given us a better indication of the effects of oxfenicine on myocardial mechanical 
function. This is a more complex model which requires more training and practise. 
 
Because this was a chronic treatment study (8 weeks) it is difficult to know whether these 
drug effects observed are due to CPT-1 inhibition in the heart or due to indirect 
(systemic) effects on other organs such as the liver, kidney or skeletal muscle. 
 
It would have been interesting to see what the effects of the drug would be on parameters 
such as fasting plasma glucose, plasma lipids, and plasma insulin as well as GLUT-4 
translocation. These are all parameters that would have to be documented in a subsequent 
study but was beyond the scope of the present project. 
 
We could not see activation of the RISK pathway because we had to record cardiac 
function at 30 minutes. At this time activity of ERK and PKB are in our experience 
already decreased. Activation could be seen when hearts were freeze clamped at 5 or 10 
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minutes reperfusion in previous studies in our laboratory. We believe documenting RISK 
pathway protein changes earlier in reperfusion may have provided different data. 
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CHAPTER 7 
 
FUTURE ENDEVORS 
 
Oxfenicine appears to achieve its positive effects, in the DIO rats, by improving 
mitochondrial respiration and activation of the RISK pathway. Furthermore, the ADP: O 
ratios were lower in the DIO rats when compared to the control rats. This is in line with 
the rest of our data which showed a decrease in cardiac function after 
ischemia/reperfusion, an increase in infarct size and an increase in oxygen consumption 
(QO2) but no change in ADP phosphorylation rates. This suggests that the level of 
obesity or the high caloric diet might be sufficient to cause oxygen wastage but not 
sufficient to influence ADP phosphorylation rates (and thus not sufficient to diminish 
ATP production). However this is in accordance with literature which indicates that the 
negative effects of diet induced obesity are not related to diminished ATP production, but 
more likely a mechanism related to tissue damage or cell death/necrosis. The positive 
effects of oxfenicine observed in the DIO rats were decreased infarct size, improved 
cardiac mechanical function, decreased oxygen consumption (QO2), increased ADP 
phosphorylation rates and increased ADP: O ratios these findings suggest that the 
underlying mechanism is related to ATP levels/production and possible reversal of tissue 
damage/cell death. Future studies could aim to investigate how oxfenicine (i) affects 
pathways involved in necrosis/apoptosis, (ii) whether it affects mitochondrial 
permeability transition pore (mPTP), Bad, Bax, Bcl-2, cytochrome-C, mitochondrial 
genes/DNA and (iii) whether oxfenicine affects Na
+
/Ca
2+
 exchange and SERCA-2a. 
 
A different mechanism appears to underlie the negative effects of oxfenicine observed in 
the control rats. Oxfenicine inhibits beta oxidation and would most probably cause 
accumulation of fatty acids, triglycerides and fatty acid oxidation intermediates which 
may lead to lipotoxicity. This has been shown in the literature (Jodalen et al. 1988; 
Greaves et al. 1984; Higgins, Faccini & Greaves, 1985; Okere et al. 2007, Finck et al. 
2005). This could then serve as a possible explanation for the negative effects of 
oxfenicine in control hearts, particularly with regards to the increase in oxygen 
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consumption (oxygen wastage). The question might arise as to why the control hearts are 
negatively affected by oxfenicine induced accumulation of fatty acids/metabolites and/or 
lipotoxicity, while DIO rats fare better. This could be explained by the fact that DIO rats 
have adapted to cope with elevated supply of fatty acids to the myocardium, -lipotoxicity 
and -accumulation of intermediates, while this may not be the case for the control hearts 
(Morse, Gluati & Reisin, 2010; Steifelhagen, 2010). Uncoupling proteins have been 
shown to have paradoxical functions and could export fatty acids out of the mitochondria 
and lead to attenuation of lipotoxicity in the DIO rats and not in the control rats (Opie & 
Knuuti, 2009). The DIO rats might have severely increased UCP levels and control rats 
not or if it is, UCP levels are only increased intermediately. While the DIO rats has 
adapted to the lipotoxicity, the control heart is not. Future studies could investigate how 
oxfenicine influences UCP expression in the metabolic syndrome, during and post 
ischemia/reperfusion. These studies could also investigate how oxfenicine affects tissue 
lipid content in the DIO rats and controls. 
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CHAPTER 8 
 
ADDENDUM TABLES 
 
Addendum 1: Effects of oxfenicine up to date (Based on literature research): 
Effect Animal Model  Author (s) Date 
(year) 
Effective treatment for patients with obstructive coronary 
artery disease & angina 
Human Bergman et al. 1980 
Has a potent effect on lactate metabolism, without any  
hemodynamic effects 
Human Naqvi et al.  1980 
Protect hearts from necrotic tissue damage during ischemia Rat Higgins et al.  1980 
Effectively increases pyruvate oxidation  Rat Higgins et al. 1981 
Can switch the heart from the oxidation of fat to glucose or 
lactate as fuel  
Dog Drake-Holland & Passingham  1983 
Protects ischemic stressed myocardium  Canine Korb et al.  1984 
Induce cardiac hypertrophy in rats and dogs, after 1-2 years of 
treatment at various dosages  
Rat & Dog Greaves et al.  1984 
Protects against ischemic damage  Rat Higgins et al.  1985 
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Effect Animal Model  Author (s) Date 
(year) 
Reduce the accumulation of long-chain acyl-carnitine in the 
ischemic myocardium after coronary artery occlusion and 
reduce infarct size  
Dog Vik-Mo et al.  1986 
Has beneficial effects on cardiac contractility and enzyme 
release in the ischemic heart  
Dog Burges et al.; Molaparast-Sales 
et al. 
1981-1987 
Oxfenicine induced cardiotoxicity Rat Bachmann & Weber 1988 
Induces the accumulation of lipid in the rat myocardium  Rat Jodalen et al.  1988 
Have beneficial effects on hypoxic rat atria  Rat Carregal et al. 1995 
Reduced concentrations of the endogenous malonyl-CoA Rat Kennedy et al.  2000 
Significantly blocked cell death induced by the combination of  
palmitate and carnitine 
Cardiomyocyte Kong et al.  2002 
Dramatically decrease palmitate oxidation, increase glucose 
oxidation and improve cardiac efficiency  
Swine Chavez et al.  2003 
Improves regional contractile power and efficiency during 
demand induced ischemia  
Swine Chandler et al.  2003 
Increase recovery of systolic pressure, cardiac output and 
ventricular contraction 
Rats Broderick & Glick  2004 
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Effect Animal Model  Author (s) Date 
(year) 
Might be effective in slowing the progression of clinical heart 
failure 
Dog Lionetti et al.  2005 
Increase mRNA levels of genes regulated by PPARα Rat & Human Rupp et al.  2005 
Reduced recovery in fasted control animals, increased their 
lactate production and attenuated contracture in fed rats  
Rat Prendes et al.  2006 
Not associated with cardiac hypertrophy in rats fed a high fat 
diet  
Rat Okere et al.  2007 
Induce a switch in cardiac energy metabolism and thereby 
increasing left ventricular mechanical efficiency, without 
affecting cardiac energy expenditure  
Swine Zhou et al.  2008 
Increased peripheral aorta resistance Rat Chang et al. 2010 
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Addendum 2: Results of clinical trials and animal studies on inhibition of fatty acid oxidation, with inhibitors other than oxfenicine: 
 
Effects/Results Animal Model Author (s) Date 
(year) 
Reduces gluconeogenesis and improves economy of  
cardiac work 
Rat Rupp et al. 2002 
Has a potent action on myosin heavy chain expression in the 
heart 
Rat Rupp et al.; Stanley et al. 2002 
Improves left ventricular function in dogs with chronic heart 
failure 
Dog Sabbah et al. 2002 
Increases theoretical ATP:O2-ratio and lowers myocardial 
oxygen consumption (MVO2) for glucose and lactate in 
comparison to long chain fatty acids 
Swine Chavez et al.; Chandler et al. 2003 
Increases cardiac mechanical efficiency under aerobic 
conditions 
Swine Chavez et al. 2003 
Reduces the symptoms of demand induced ischemia and results 
in improved regional systolic function  
Swine Chandler et al. 2003 
Prevents left ventricular remodelling and delays 
decompensation in pacing-induced heart failure 
Dog Liovetti et al. 2005 
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Effect Animal Model  Author (s) Date 
(year) 
Long-term treatment improves functional class and left 
ventricular function in patients with HF 
Rats, human, dog 
& swine 
Fragasso et al. 2006 
Reduces myocardial infarct size without affecting 
hemodynamic 
Rat Sesti et al. 2006 
Improves cardiac pump function and slows the progression of 
heart failure 
Rat Lopaschuk 2006 
Reducing the formation of reactive oxygen species (ROS) and 
improves reperfusion mechanical function 
Human Bhandari et al. 2007 
Is not associated with cardiac hypertrophy in rats fed a high fat 
diet 
Rat Okere et al. 2007 
Decreases myocardial oxygen consumption and improves 
cardiac efficiency in demand-induced ischemic heart 
Rat Wu et al. 2008 
Improves left ventricular mechanical efficiency by increasing 
left ventricular power for a given rate of myocardial energy 
expenditure 
Dog Zhou et al. 2008 
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Effect Animal Model  Author (s) Date 
(year) 
Increases efficiency of ATP production, decreases the 
production of lactate and protons and decreases the 
accumulation of harmful fatty acid metabolites 
Rat & human Lopaschuk; Dyck & Lopaschuk 2008 
Had no effects on the post-MI occurrence of LV dysfunction or 
remodelling 
Rat Mouquet et al. 2009 
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